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1 Introduction 
1.1 Bone Morphogenetic Proteins 
1.1.1 Milestones in History 
As it seems typical for ground breaking discoveries, the key find triggering an 
avalanche of intense research was made by chance, based on a failed experi-
ment of Marshall Urist in 1965. He demineralized rabbit and rat bone matrix with 
0.6 M HCl, treated some of the samples with CaCl2 to create nucleation sites 
and implanted both the treated as well as the untreated control samples 
intramuscularly in rodents. Surprisingly, the control samples exhibited the for-
mation of new bone within few weeks after implantation [Urist, 1965]. What 
happened? The demineralized bone matrix seems to contain substance(s) res-
ponsible for the observed morphogenesis. Morphogenesis describes the com-
plex process of differentiation and growth of the structure of a part of or the 
whole organism – herein the development of a vascularized spherical ossicle 
with functioning bone marrow. Urist attributed this phenomenon to certain bone 
matrix derived proteins, coining the term “bone morphogenetic protein” to 
describe them, and in the following years, he succeeded in corroboration of his 
hypothesis [Urist et al., 1971] by identification of the protein fraction responsible 
for the effect.  
The isolation and characterization of bone morphogenetic proteins (BMPs) was 
hampered by the minimal amounts present in bone as 1 kg bone only contains 
approximately 1-2 µg BMPs [Wang et al., 1988]. Consequently, laborious purifi-
cation procedures were necessary to obtain at least partially purified extracts. 
The introduction of dissociative extractants [Sampath et al., 1981] led to an 
improvement of the extraction technique, increasing the availability of highly 
purified bone inducing proteins. The development of a satisfactory bioassay and 
advances in molecular biotechnology made it possible to encode the amino-acid 
sequences of purified bovine bone extracts. In 1988, Wang and coworkers 
succeeded in isolation and characterization of three polypeptides subsequently 
named BMP-1, BMP-2 and BMP-3 [Wang et al., 1988]. Knowing their amino 
acid sequence, oligonucleotide probes could be synthesized and used to screen 
the human genes for the encoding DNA sequences [Wang et al., 1987]. 
Transfection of the full length cDNA via mammalian expression vectors into 
Chinese hamster ovary cells finally led to the production of the first recombinant 
human bone morphogenetic proteins (rhBMPs) [Wang et al., 1989]. 
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1.1.2 Biochemistry 
1.1.2.1 BMP-2 and its Family 
BMP-2 is only one representative of the large bone morphogenetic protein 
family. BMPs are highly conserved across different animal species. At least 15 
individual human BMPs are currently recognized (Figure 1-1) [Einhorn, 2003]. 
RhBMP-2 and rhBMP-4 to rhBMP-7 have proven to be osteoinductive in the rat 
subcutaneous assay. Interestingly, BMP-3, which is most abundant in bone, 
failed to develop new bone and is believed to represent an inhibitor [Baha-
monde et al., 2001]. With the exception of BMP-1, that has proven to be a 
metalloproteinase [Hofbauer et al., 1996], BMPs are multifunctional cytokines 
belonging to the large group of the Transforming Growth Factor β gene super-
family, currently including approximately 45 genes [Rueger, 2002]. They are 
synthesized as large precursors consisting of an N-terminal signal sequence, a 
poorly conserved prodomain and a mature domain at the carboxy terminus. The 
latter contains 7 highly conserved cysteine residues. Six of them join in three 
intramolecular disulfide bridges, building the cystine-knot folding motif: two 
cysteine bridges form a ring-like structure with the main chain, wide enough for 
the third disulfide bridge to pass through [Scheufler et al., 1999]. The remaining 
cysteine participates in a disulfide bridge with the cysteine of another molecule, 
enabling the formation of homodimers in case of linkage with an identical 
monomer or heterodimers by dimerization of two different members. 
Table 1-1: BMP family (modified from Reddi, 2000) 
BMP Subfamily generic name BMP designation 
BMP-2A BMP-2 
BMP-2/4 
BMP-2B BMP-4 
Osteogenin BMP-3 
BMP-3 
GDF-10 (growth/differentiation factor) BMP-3B 
BMP-5 BMP-5 
Vgr-1 (vegetal related) BMP-6 
OP-1 BMP-7 
OP-2 BMP-8 
OP-3 BMP-8B 
OP-1  
(ostogenetic 
protein)/BMP-7 
GDF-11 BMP-11 
Introduction - Bone Morphogenetic Proteins 3 
BMP Subfamily generic name BMP designation 
CDMP-1/GDF-5 BMP-14 
CDMP-2/GDF-6 BMP-13 
CDMP (cartilage 
derived morpho-
genetic protein) CDMP-3/GDF-7 BMP-12 
BMP-9 BMP-9 
BMP-10 BMP-10 
BMP-15 BMP-15 
others 
BMP-16 BMP-16 
 
1.1.2.2 Features of rhBMP-2 
RhBMP-2 is secreted by genetically engineered CHO (Chinese hamster ovary) 
cells as a dimeric glycoprotein of approx. 30 KDa [Wozney et al., 1988]. The 
carbohydrate moiety has proven to be not important for biological activity 
[Rueger, 2002], and methods to produce active BMP-2 in Escherichia coli are 
also described [Ruppert et al., 1996, Zhao et al., 2002]. The structure of a BMP-
2 monomer is descriptively associated with a ‘hand’ consisting of two ‘fingers’ of 
antiparallel β-strands and a α-helical region at the ‘wrist’ (Figure 1-1a, b) 
[Rueger, 2002]. Dimer formation can illustrative be figured as a handshake. 
Beside the covalent disulfide bond, interactions between the α-helix and the β-
sheets of the neighboring molecule further support the intersubunit contact. 
RhBMP-2 dimer formation involves three monomer variants: the mature 
monomer (Q), consisting of 114 amino acids, an extended form with a pro-
longed sequence of 17 amino acids at the N-terminus (T), and an alteration of 
the mature form, with isomerization of the N-terminal glutamine into the pyro-
glutamate form (<Q) [Friess, 2000]. Consequently, 6 dimeric isoforms are 
possible (Figure 1-2). All of them have proven to be active in an in vitro cell 
culture assay.  
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Figure 1-1: Topology diagrams of BMP-2: (a) schematic drawing: Helices are 
indicated as cylinders, β-strands as arrows; disulfide bridges are dotted 
(modified from Friess 2000 and Scheufler et al. 1999) (b) three 
dimensional folding of the native BMP-2 dimer: α-helices are indicated as 
spiral, β-strands as arrow (modified from Scheufler et al. 1999) 
 
Figure 1-2: Combination among 3 different monomers, the mature monomer (Q), an 
isomerized pyro-glutamate mature form (<Q) and an extended form (T) 
leads to 6 dimeric isoforms. 
With an isoelectric point (pI) of 8.2 ± 0.4, BMP-2 is a highly basic protein 
[Abbatiello et al., 1997]. The need of chaotropic agents for satisfied extraction of 
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natural occurring BMPs underlines its limited solubility in water. The highly 
hydrophobic surface of the dimer, as it can be seen in Figure 1-3a, provides an 
explanation for this (modified from Scheufler et al., 1999). Furthermore, BMP-2 
exhibits a unique solubility profile (Figure 1-3b): increasing the ionic strength 
initially causes a rapid decrease in solubility, being minimal at approx. 0.15 M, 
followed by an increase at intermediate ionic strengths. Above approx. 0.5 M, 
classic salting-out is observed [Abbatiello et al., 1997]. The fact that solubility is 
minimal at physiologic conditions is thought to be relevant for its pharmacologic 
effect.  
        
Figure 1-3: (a) Solvent accessible surface of BMP-2: white areas depict hydrophobic, 
blue positive and red areas negative surface charges (modified from 
Scheufler et al., 1999); (b) solubility behavior of rhBMP-2 at pH 7.2 for 
NaCl (?) and Na2SO4, (?): before approx. 500 mM, solubility correlates to 
the ionic strength, at higher concentrations, salt specific salting out is 
observed in pH given (adapted from Abbatiello et al., 1997). 
1.1.2.3 Signaling Pathway 
Two different BMP receptors, BMPR-I and BMPR-II are known. The individual 
receptors have a weak affinity for the BMP dimer, but binding to both types 
occurs with high affinity leading to the formation of a heteromeric complex 
(Figure 1-4a). Within this complex, the constitutively active BMPR-II receptor 
kinase phosphorylates the GS domain of BMPR-I. In the ‘cannonical’ pathway, 
intracellular signaling is mediated by Smad proteins. The Smads can be divided 
into three subclasses: receptor-regulated Smads (R-Smads), common-mediator 
Smads (Co-Smads, i.e. Smad 4) and inhibitory Smads (I-Smads, i.e. Smad 6 
and 7). Upon BMP receptor activation, R-Smads (Smad 1, 5, and 8) are phos-
phorylated and form heteromeric complexes with Co-Smad 4. The trimeric 
Smad complex translocates to the nucleus and activates the transcription of 
early BMP-responsive genes. I-Smads (Smad 6 and 7) display their negative 
regulation by inhibition of the phosphorylation of R-Smads (Figure 1-4b). The 
‘noncanonical’, mitogen-activated proteinkinase (BMP-MAPK) pathway is 
ionic strength [mM] 
so
lu
bi
lit
y 
[%
] 
a b
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thought to be responsible for BMP induced apoptosis and inhibition of trans-
cription factors [Botchkarev, 2003]. Extracellularly, the activity of BMPs is 
modulated by diffusible antagonists (noggin, chordin, follistan), preventing their 
binding. 
Despite the increased knowledge about the receptors and the signaling 
pathways, the understanding of the complex interplay of different growth factors 
during bone formation and bone repair is still limited. There is general 
consensus that there must be a so-called cross talk between the various 
signaling pathways, but the elucidation of the underlying mechanisms is still in 
its early stages [Lieberman et al., 2002]. 
 
 
Figure 1-4: (a) Receptor activation; (b) intracellular signalling cascade of the 
‘cannonical’ pathway (modified from Korchynsky et al., 2002) 
a b
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1.1.2.4 Pharmacokinetics of rhBMP-2 
Due to its short serum half life, BMP is usually combined with a carrier (1.1.4). 
Therefore, a discussion of the release profile of BMP from different carriers 
must consider the property of BMP to bind to various materials, e.g. 
hydroxylapatite/tricalcium phosphate [Friess et al., 1997] or collagen [Friess, 
2000], explaining its incomplete release from these systems. The existence of a 
binding site for heparin, which strongly influences its activity, is described by 
Ruppert [Ruppert et al., 1996]. The in vitro release profile is also strongly 
influenced by the properties of the release medium, reflecting the dependence 
of BMP solubility on pH and ionic strength. For collagen sponges, an initial burst 
is reported, releasing 50-80 % of the dose within the first day [Geiger, 2001]. In 
vitro studies utilizing serum as release medium demonstrate a sustained 
release over 14 days [D'Augusta et al., 2000]. In vivo studies in the well 
established rat ectopic model unclose a more differentiated picture: an initial, 
rapid rhBMP-2 loss is followed by a monoexponential decrease of BMP 
concentration from the sponge [Winn et al., 1998]. Further studies compare the 
osteoinductive activity of rhBMP-2 with a modified variant (plasmin cleaved 
rhBMP-2) that shows a stronger initial burst and subsequently lower local levels 
over time. Although the cleaved BMP variant has a higher activity in cell culture 
[Abbatiello et al., 1997], its in vivo osteoinductive activity is significantly less 
than the native rhBMP-2 [Winn et al., 1999]. This observation provides strong 
evidence that sustained release is a critical pharmacokinetic parameter for 
osteoactivity. The initial retention at the implant site is also a function of the 
isoelectric point, with molecules of lower pI disappearing faster [Uludag et al., 
2001]. It is hypothesized that ‘bound’ BMP launches its effect not only in terms 
of an increased effective local concentration, but also may potentiate its activity 
by being presented in this form to target cells.  
1.1.3 Biologic Activity: Mechanism of Ossification 
The development of new bone can follow two different pathways. Endochondral 
ossification refers to formation of bone with a cartilage intermediate and can be 
found e.g. in long bone development. Direct bone formation without a cartila-
ginous intermediate, as it is the case in the scull and the face is called intra-
membranous ossification [Zhao M. et al., 2002]. The mechanisms determining 
the ossification pathway are not completely understood. In vitro, bone formation 
has been shown to be concentration dependent, being endochondral at high 
and intramembranous at low doses of BMP [Lindholm, 1996]. Preclinical studies 
suggest that the anatomic site at which BMP is administered also determines 
the formation pathway [Smith, 1994]. The cascade of events induced by 
rhBMP-2 applied to a matrix implanted ectopically mimics early stages of 
embryonic bone formation and postnatal endrochondral ossification. RhBMP-2 
acts as a growth and differentiation factor [Valentin-Opran et al., 2002]. On a 
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cellular level, undifferentiated mesenchymal-type cells initially infiltrate the 
periphery of the matrix by chemotaxis and proliferate. After differentiation into 
chondroblasts, these cells secrete extracellular matrix and create a 
cartilaginous template, which hypertrophies. At the same time, vascularization 
by haematopoietic and endothelial cells occurs, a prerequisite for osteoblast 
differentiation [Reddi, 2001]. The complex process temporally extends from the 
periphery toward the center of the implant, potentially connected with 
degradation of the implant. Remodeling of the cartilage and trabecular bone by 
osteoblasts and osteoclasts finally results in the formation of woven bone with 
vivid marrow core [Kirker-Head, 2000, Valentin-Opran et al., 2002]. The 
described bone formation can be subdivided into two underling principles: 
osteoinduction and osteoconduction. Osteoinduction - provided by BMPs 
present within the matrix - refers to the ability to induce proliferation of 
undifferentiated mesenchymal-type cells and formation of osteoprogenitor cells 
with the capacity to form bone. Osteoconduction is a process attributable to the 
matrix, supporting the ingrowths of capillaries and cells into its three-
dimensional scaffold geometry [Einhorn, 2003].  
1.1.4 Delivery Systems  
Closely associated with the BMP research is the development of an adequate 
carrier to create a clinical device for the field of bone reconstruction. A lot of 
different matrixes have been evaluated in numerous studies in combination with 
osteoinductive BMPs. In the course of this development, a number of general 
features for an ideal carrier were compiled [Friess, 2000, Geiger, 2001, Kohnert, 
2003]: 
• biocompatibility, low immunogenicity and antigenicity 
• relative insolubility in physiological conditions 
• protection against proteolytic activities 
• biodegradability  
• amenability to sterilization 
• adequate compressive and tensile strength  
• adequate porosity for cellular invasion and vascularization 
• enhancement of cellular attachment 
• affinity to BMPs and host bone 
• enhancement of osteogenic activity of BMP with a restrictive release of 
BMP at an effective dose during a period coincident with the 
accumulation and proliferation of target cells 
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Collagen-based carriers have proven to be most suitable and were used in 
clinical settings. The failure to identify a delivery vehicle meeting all the criteria 
implies that different specific applications define their individual requirements to 
the matrix. Improvement in minimally invasive surgical techniques, as well as 
the desire to expand the potential application of BMP, e.g. healing of closed 
fractures puts emphasis on the development of formulations that can be applied 
by local injection. Injections of BMPs delivered in buffers have already shown to 
accelerate healing of closed fractures in rats [Einhorn et al., 2003] and in 
osteotomy sites in rabbits [Ruhe et al., 2003]. However, the success of pure 
buffer formulations in large animals is limited due to insufficient responsive cells 
and insufficient retention at the repair site [Seeherman et al., 2003]. To prolong 
the retention of BMP at the site of action, different materials are currently under 
investigation, covering the mayor categories of inorganic materials (calcium 
cements), synthetic polymers (PLA, PGLA), natural polymers (hyaluronan) and 
combinations thereof with embedded ceramics or protein loaded microparticles. 
Promising results in a rabbit osteotomy model were achieved with calcium 
phosphate cement as carrier, and large animal and nonhuman studies are 
awaited to confirm these findings [Ruhe et al., 2003].  
1.1.5 Applications of BMPs 
Whereas numerous investigations show the potential clinical efficacy of BMPs 
in the treatment of skeletal disorders, currently only three clinical trials have 
supported the use of recombinant bone morphogenetic proteins, leading to FDA 
(Food and Drug Administration) approval for specific indications [Einhorn, 
2003]. 
1.1.5.1 Use of rhBMP-2 in Spinal Fusion Applications 
Surgical techniques for spinal fusion and standard of care (SOC): 
Spinal fusion describes a surgical treatment aiming the bridging of two (single 
level) or three (two-level) vertebras by formation of solid bone between them. 
This might become necessary when pain in the lower back or the legs arises 
from irritated nerve endings or even entrapped nerves located at the level of the 
vertebras. By fixation, motion across the damaged level is eliminated and so is 
the trigger for pain. Indications for such a surgical procedure are disorders of 
the spine, such as recurrent disc herniation, lumbar spondylolisthesis, scoliosis, 
severe disc degeneration or a traumatic injury of the spine, such as a fracture. 
(www.spineuniverse.com). According to the procedure, two different types of 
spine fusion scenarios can be distinguished. In the ‘anterior interbody 
approach’, the surgery will be performed from the front via an incision in the 
patient’s abdomen, and the space between the vertebral bodies is targeted to 
be bridged. The ‘posterior spinal fusion’, also referred to ‘posterolateral 
approach’ is performed from the back and the rigidity of the vertebras should be 
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achieved by inducing new bone between the spaces of the transverse 
processes (www.espineinstitute.com).To establish a novel therapeutic regimen, 
safety and efficacy have to be proven. Efficacy can be demonstrated by 
equivalence to SOC [Einhorn, 2003]. Preferred bone graft material is autolo-
gous bone, i.e. graft originating from the same individual (autograft). It unites all 
three prerequisites for new bone formation: It supplies potent bone forming 
cells, i.e. osteoblasts or its precursors (osteogen), depicts osteoinductive and 
osteoconductive properties. The main disadvantage of autografts is the 
necessity to harvest them from the patient in an additional surgery which is 
accompanied by a number of problems, e.g. donor site pain, increased blood 
loss during surgery and a higher risk of infection. 
Posterolateral approach with rhBMP-2: 
In several animal models, reaching from low vertebrates to nonhuman primates, 
the use of endogenous and recombinant BMP in spinal fusion has been 
evaluated. In a validated rabbit model posterolateral fusion was aimed, com-
paring rhBMP-2 with control autograft. A 100 % fusion rate within 4 weeks after 
implantation was achieved. Bone formation, consolidation and remodeling were 
greater in the rhBMP-2 treated group, and the fusions were biomechanically 
stronger and stiffer than the control [Schimandle et al., 1995]. However, transfer 
of the promising results achieved in low animals to a nonhuman primate animal 
model initially failed. Martin et al. found out that higher concentrations were 
necessary in primates, compared to lower animals. Furthermore, his studies 
revealed the need of compression resistant carriers, as muscle compression of 
the device take place in the posterolateral fusion application [Martin, Jr. et al., 
1999]. In awareness of this data, a compression resistant carrier composed of 
hydroxylapatite and tricalcium phosphate was developed and demonstrated 
efficacy of rhBMP-2 in a nonhuman primate model, whereas no fusion could be 
achieved in the autograft control group [Boden et al., 1999]. The successful 
components were incorporated into a collagen sponge to obtain a moldable 
matrix which is loaded with BMP before application. Again, the device has 
proven 100 % fusion in a rabbit and rhesus monkey model, and comparison 
with historical controls treated with autograft indicates higher stiffness. Preclini-
cal studies in a nonhuman primate animal model have shown that combinations 
of an rhBMP-2 soaked absorbable collagen sponge with allograft chips or 
restorable ceramic granules also leads to 100 % fusion, whereas fusion in con-
trol group treated with autograft is only achieved in 33 % [Sandhu et al., 2003]. 
Up to now two pilot clinical trials in humans were preformed with rhBMP-2 
loaded biphasic calcium phosphate (BCP) carriers for the posterolateral lumbar 
fusion environment [Boden et al., 2002]. Both studies suggest the superiority of 
the artificial BMP/BCP device compared to autograft. A 100 % fusion rate was 
observed in all BMP-2/BCP treated patients, thus determining effective doses of 
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BMP for this application. Furthermore, the influence of instrumentation was 
evaluated and a threshold was defined where fusions can be achieved without 
additional fixation. Studies including larger patient groups were awaited to 
confirm these findings, paving the way for approval of an rhBMP-2 carrier in the 
posterior lumbar fusion environment. 
Interbody fusion approach with rhBMP-2: 
The first preclinical study, using an interbody cage augmented either with 
rhBMP-2 or with autogenous iliac-crest bone graft for lumbar interbody fusions 
in a sheep model showed superiority of the BMP group compared to the 
autograft control group with respect to histologic evaluation of fusion rate after 6 
months (37 % vs. 100 % fusion rate). The rhBMP-2 induced fusions had 
significantly less fibrous-tissue ingrowths along the cage fenestrations than the 
control [Sandhu et al., 2002]. Similar outcomes were achieved by Zdeblick in a 
goat model, comparing titanium fusion cages filled either with an rhBMP-2 
soaked collagen sponge or with autograft (95 % vs. 48 % fusion rate) [Zdeblick 
et al., 1998]. With success evident in lower animals, Boden et al. tested the 
efficacy of two different concentrations of rhBMP-2 in combination with a 
collagen sponge entrapped in a titanium fusion cage in rhesus monkeys for 
spinal fusion. Although both concentrations succeed in bridging, bone formation 
was quicker and denser in response to the higher concentration of 1.5 mg/ml 
[Boden et al., 1998]. Comparison of rhBMP-2/collagen carrier with autogenous 
bone graft, both implanted in combination with allograft dowels in rhesus 
monkeys for interbody fusion, depicts the inferiority of the latter in respect to 
fusion rates after 6 months. In addition, the rhBMP-2/collagen/allograft 
composition had undergone complete remodeling [Hecht et al., 1999]. A 
recently published study elucidates the effectiveness of rhBMP-2 in combination 
with a composite sponge (collagen-hydroxylapatite-tricalcium phosphate carrier) 
in pigs. Herein, a minimally invasive surgical technique in combination with 
instrumentation was used. The observed bone formation was significantly 
greater in the BMP treated group. Additionally, the rhBMP-2 containing carrier 
achieves the best fusion score, followed by nearly similar scores for autografts 
harvested form either the iliac crest or the rib [Sucato et al., 2004]. 
The promising results prompted the FDA to give approval to a series of pilot 
IDE1 studies in humans [Sandhu et al., 2003]. The first one involved 14 patients. 
A small control group of 3 people were treated in an open approach with a 
titanium cage (Lumbar Tapered Cage: LT-Cage®) filled with autograft derived 
from the iliac crest. 11 patients received the LT-Cage® filled with an rhBMP-2 
                                            
1 Investigational Device Exemption: An IDE approval allows the use of an investigational device 
in a clinical study to collect safety and effectiveness data required to support a Premarket 
Approval (PMA) (http//www.fda.gof/). 
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soaked collagen sponge (referred to Infuse®), either in an open approach or in a 
laparoscopic surgery [Boden et al., 2000]. Whereas fusion failed in one of three 
cases in the control group, successful fusions were achieved in all patients of 
the experimental cohort. To address the question of antibody formation as 
possible immune response to either the rhBMP-2 or the bovine derived collagen 
sponge, serum analyses were performed. No patient treated with rhBMP-2 
reveals higher antibody titers after surgery. Three patients had increased 
antibovine-collagen type I titers, but no relevant side effects were observed. 
This study demonstrates the safety of rhBMP-2 in humans and its feasibility to 
induce bone inside intervertebral fusion cages. Furthermore, it confirms the 
deployed rhBMP-2 concentrations of 1.5 mg/ml to be effective. Although statis-
tical analysis is precluded due to the small number of patients, the outcome also 
suggests that the rhBMP-2 device is at least equivalent to SOC, autogenous 
iliac crest bone graft. Finally, the suitability of the study design was confirmed. 
These results lay the groundwork for a larger pivotal trial enrolling 415 patients 
requiring anterior lumbar interbody fusion. 143 patients received the LT-Cage® 
filled with Infuse® in a classical open approach. 116 patients received the same 
device in a laparoscopic, i.e. minimally invasive approach. The control group 
consists of 116 patients and received the LT-Cage® filled with iliac crest derived 
autograft. The highest fusion rates were obtained in the classic open approach 
of the Infuse® treated cohort, achieving fusion in all patients 24 months after 
surgery. Beside the fusion rate, a 15 point improvement in the Oswestry score, 
a self-report questionnaire evaluating disability and pain, was used as criterion 
of success [Fairbank et al., 1980]. After 12 months, the success rate was 
76.9 % (100 of 130) in the open Infuse® cohort, 75.2 % (94 of 125) in the 
autograft cohort, 79.8 % (91 of 114) in the cohort that obtained the Infuse®/LT-
Cage® by laparoscopic insertion. The prevalence of rhBMP-2 antibody forma-
tion evaluated 3 months after surgery was below 1 % in all cohorts. Prevalence 
for antibodies against bovine type-I collagen was highest in the laparoscopic 
cohort (24.8 %), and similar within the autograft and open Infuse® cohort 
(13.1 % and 12.9 % respectively). However, these antibody responses could 
not be associated with adverse side effects. Significant improvement in respect 
to operative time and blood loss were yielded in the Infuse® group. Additionally, 
more than one third of the autograft-harvested patients suffer from donor site 
pain 2 years following surgery. Consulting the results of a previous study 
enrolling 266 patients treated with iliac crest filled LT-Cages® in a laparoscopic 
approach, the median time to return to work was 116 days in the Infuse® group 
and 170.5 days in the iliac-crest bone-graft group. This study assessed the 
safety, efficacy and the therapeutic benefits of Infuse® combined with the LT-
Cage® for spinal fusions and led to FDA approval in USA on July 2002 for the 
treatment of spinal degenerative disc disease.  
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Table 1-2: Products approved in the USA and the EU containing rhBMPs (BMP-2 or 
OP-1) 
trade name approval/ date description indication 
Osigraft® 
(INN: 
Eptotermin 
alfa) 
Novos 
Medicinal 
product for 
human use: 
August 21, 
2001 
osteogenic protein 1 
powder for suspension 
for intraosseus 
implantation 
treatment of non-union 
of tibia of at least nine 
month duration 
OP-1® 
Implant 
HDE2: 
October 17, 
2001 
human OP-1 powder 
and bovine collagen 
mixed with saline so-
lution to form a paste 
treatment of fractured 
bones failed to unite 
without intervention 
Infuse® 
Bone Graft/ 
LT-CAGE® 
Lumbar 
Tapered 
Fusion 
Device 
PMA3:  
July 2, 2002 
LT-CAGE:  
metallic tapered spinal 
fusion cage;  
Infuse®:  
rhBMP-2 soaked on an 
absorbable collagen 
(bovine type-I) carrier 
device to support fusion 
of vertebrae in the lower 
spine without the 
necessity for auto-
grafting 
InductOs® 
(INN: 
Dibotermin 
alfa) 
Medicinal 
product for 
human use: 
July 1st, 
2002 
Implant kit for 
periosseous use 
containing rhBMP-2 
soaked on a matrix 
after reconstitution 
adjunct treatment of 
acute, open tibia 
fractures in adults in 
combination with SOC 
(open fracture reduc-
tion, intramedullary nail 
fixation) 
OP-1 Putty HDE: 
April 7, 2004
mixture of genetically 
engineered OP-1 with 
bovine collagen, sterile 
saline water and a 
thickening agent for-
ming a putty-like 
material 
posterolateral spinal 
fusion in patients who 
are not able to provide 
autograft material and 
failed a previous spinal 
fusion surgery 
Infuse® 
Bone Graft 
PMA: 
April 30, 
2004 
absorbable collagen 
sponge (bovine origin) 
soaked with rhBMP-2 
aiding the healing of 
fresh, open fractures of 
the lower leg bone (ti-
bia) in combination with 
internal stabilization  
                                            
2 Humanitarian Device Exemption: An application approved under HDE must demonstrate that 
the device does not pose an unreasonable or significant risk of illness or injury, and that the 
probable benefit to health outweighs the risk of injury or illness from its use; results of 
scientifically valid clinical investigations are not required (http//www.fda.gof/). 
3 Premarket Approval: The application submission must provide valid scientific evidence 
collected from human clinical trials showing the device is safe and effective for its intended 
use ([Bauer et al., 2002]; http//www.fda.gof/).  
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1.1.5.2 Use of rhBMP in the Treatment of Non-unions 
Another successful application for BMP is its use in supporting or accelerating 
fracture repair. A series of studies evaluated the potential of genetically 
engineered BMPs in humans for the treatment of large segmental bone defects 
[Cook et al., 1994, Geesink et al., 1999]. The crucial study leading to FDA 
approval for treatment of non-unions of the tibia was performed from 
Friedlaender et al. enrolling 122 patients. They demonstrated the safety of 
rhOP-1 supplied in conjunction with type I bovine bone-derived collagen and its 
equivalence to the SOC, the treatment with autograft, without the disadvantage 
of the latter of an additional harvesting operation site [Friedlaender et al., 2001]. 
Even superiority of an adjuvant treatment with an rhBMP-2 soaked collagen 
sponge in combination with SOC to SOC alone was demonstrated in the 
BESTT (BMP-2 Evaluation in Surgery for Tibia Trauma) study enrolling 450 
patients. A significant increase in the rate of fracture-healing, measured by 
radiographic assessment and decreased number of secondary intervention after 
12 months, could be demonstrated in patients treated with 1.5 mg/ml rhBMP-2. 
The number of fracture site infections in the subset of patients with the most 
severe tibia fractures was significantly lower, and accelerated soft-tissue 
healing could be observed.  
1.1.5.3 Further Potential Applications 
The currently available products demonstrate the usefulness of rhBMPs as 
osteoinductive component in bone graft substitutes and as adjuvant to SOC to 
accelerate and support fracture healing of delayed and non-unions and 
emphasize their importance in the field of orthopedic surgery. Promising results 
in related fields of tissue engineering demonstrate that the full potential of BMPs 
is not jet taped. However, a lot of work still has to be done to elucidate and 
optimize the ideal delivery strategy for the targeted indication. 
Use in oral-maxillofacial surgery: 
The successful augmentation of the alveolar ridge has been reported by Howell 
and coworkers [Howell et al., 1997]. The same carrier was tested by Boyne and 
colleagues for augmentation of the maxillary sinus floor [Boyne et al., 1997]. 
The feasibility of rhBMP-2 implanted with a collagen carrier to heal simulated 
critical-sized maxillofacial defects in subhuman primates has been demonstra-
ted by Boyne and colleagues [Boyne, 2001]. Marukawa and coworkers 
succeeded in functional reconstruction of the mandible in non-human primates 
using rhBMP-2 [Marukawa et al., 2002]. Pivotal clinical trials for this indication 
are underway [Valentin-Opran et al., 2002]. The potential of some BMPs to 
induce new dentin could be demonstrated. The size, shape and kind of osteo-
inductive carrier greatly influence the outcome and needs further evaluation 
[Nakashima et al., 2003]. Therefore, the use of BMPs in periodontal and dental 
diseases is in its early states. 
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Tendon repair and cartilage regeneration: 
In contrast to bone, cartilage has a limited capacity to heal after injury. The 
repair tissues achievable with currently available methods still differ from 
healthy articular cartilage in respect to stiffness, morphology and biochemical 
composition [Aigner et al., 2003]. A promising concept should cover three 
important aspects. First, due to the limited number of potential responsive cells 
available in the adult articular cartilage, the introduction of a new cell population 
seems to be advantageous. A second aspect is the delivery of cytokines and 
growth factors with the aim to increase the metabolic activity of the cells and to 
support the induction of the regenerative process. Finally, an appropriate carrier 
matrix is required for both the cells and the growth and differentiation factors. 
For success, the release kinetics of promising growth and differentiation factors 
are of mayor concern. As bone morphogenesis is a sequential cascade with a 
cartilagenous intermediate formed (endrochondral ossification), BMPs are as 
well cartilage morphogenetic proteins. The chondro-inductive property of a 
single BMP-2 injection was demonstrated in murine knee joints [van Beuningen 
et al., 1998]. Application of BMP-2 via an adenoviral approach (vectors carrying 
complementary DNA of rhBMP) also resulted in the induction of new cartilage 
and extensive osteophyte formation [Gelse et al., 2001]. The repair of full thick-
ness defects in the articular cartilage of rabbits can be improved with an 
rhBMP-2 impregnated collagen sponge, as demonstrated by Sellers and 
coworkers. One year after implantation, the histological appearance of the 
rhBMP-2 treated defects were significantly better than untreated defects [Sellers 
et al., 2000]. Forslund and co-workers evaluated the potential of tendon healing 
with cartilage derived morphogenetic proteins (CDMPs, Table 1-1) and OP-1 
[Forslund et al., 2003]. A series of other members of the transforming growth 
factor superfamiliy showed effectiveness in chondrogenetic tissue induction. 
However, the incidence of undesired side effects was lower within the BMPs 
[Hunziker et al., 2001]. In the future, not only focal defects of articular cartilage, 
but also diseases affecting the joints more generally such as osteoarthritis or 
rheumatoid arthritis might benefit from a controlled delivery of BMPs [Kaps et 
al., 2002]. 
Osseointegration: 
Improved adhesion and proliferation of BMP-2 pretreated osteoblastic cells on 
titanium alloy often used for orthopedic implants was demonstrated in cell 
culture [Shah et al., 1999]. Therefore, enhanced osseointegration of implants 
might be achieved by bonding BMPs to screws, pins, joint prosthesis or other 
implant surfaces [Kirker-Head, 2000]. Hartwig and coworkers demonstrate the 
positive effects on osseointegration of BMP coated composite titanium implants 
[Hartwig et al., 2003].  
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Metabolic bone diseases: 
Apart from the indications requiring local BMP delivery, there are also 
indications that might benefit from a systemic application. Osteoporosis, a 
disease characterized by excess bone fragility due to a loss of bone mass and 
alterations in bone microarchitecture, is in part the result of a reduced number 
of osteoprogenitor cells and reduced differentiation into osteoblasts [Fromigue 
et al., 2004] – events BMPs have proven to be effective. Depressed BMP levels 
are reported in patients with osteoporosis [Kirker-Head, 2000]. BMP-2 and 
BMP-7 have shown to up-regulate modulators within the bone responsible for 
bone density increase [Nemec et al., 2001]. Further evidence is provided by the 
bone anabolic effect of statins, which are known to be BMP-2 inducers [Koida et 
al., 2004]. Simple systemic administration of soluble BMP is not feasible due to 
the rapid clearance in the liver, resulting in a short serum half life. An injectable 
sustained releasing formulation might overcome the obstacle of short serum 
half live. However, the question of side effects still needs to be addressed. 
Intraosseous injection of a sustained releasing formulation might be another 
thinkable scenario. Morbus paget, characterized by accelerated bone remode-
ling due to increased bone katabolic processes, might also benefit from the 
osteoinductive properties of BMPs [Nemec et al., 2001]. 
Actions beyond bone: 
The discovery of BMP as modulators in bone formation has attracted the 
attention of research on potential applications in the field of skeletal surgery. 
With the elucidation of BMPs molecular genetics, their expression pattern and 
gene depletion experiments, a more fundamental role of the BMPs became 
apparent. BMPs have demonstrated to be also involved as differentiation 
factors and physiological regulators in a series of soft tissues, including the skin, 
the nervous system, the eye, the urogenital system, the kidney, and the 
cardiovascular system [Martinovic et al., 2002 Reddi, 2001]. Within wealthy 
skin, BMPs are involved in the regulation of hair follicle growth, melanogesis 
and innervation and in the differentiation and proliferation of the epidermis, 
making them attractive candidates for applications in the field of wound healing, 
proliverative skin disorders and corrections of hair growth disorders 
[Botchkarev, 2003]. The observation that BMP-7 reduces the severity of injury 
after renal failure might also gain clinical relevance [Martinovic et al., 2002]. 
Multiple uses in a variety of clinical indications are foreseeable, and it was even 
suggested to re-name them ‘body morphogenetic proteins’ to measure up to 
their wide-ranging role. 
The possible benefit from immobilized BMP, (i) the importance of sustained 
release for osteoinduction, (ii) the desire for an injectable formulation to over-
come the necessity of “open” surgical approaches required for the implantation 
of rigid carriers (see 1.1.4) and (iii) to serve as formulation for new emerging 
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indications (see 1.1.5.2) mark the key requirements for an innovative 
formulation. A particulate rhBMP-2 formulation can cover the desired features.  
1.2 Formation of Protein Particles by Precipitation  
A particulate protein formulation offers a series of advantages. It provides a 
carrier free sustained releasing delivery system that can be injected as a 
suspension. In addition, it has the potential to be used in alternative adminis-
tration routes, such as pulmonal delivery, or as a component in more complex 
controlled release formulations, e.g. incorporation in implants or microspheres. 
According to the concept of improved stability in the solid-state [Maa et al., 
2000], a particulate formulation might be superior to a liquid formulation. 
Furthermore, large amounts of protein can be administered in a small volume. 
In some cases, an increased therapeutic effect may arise from the presentation 
of immobilized protein to the target cells. A number of techniques are currently 
available to prepare relatively pure, dry protein particles. 
1.2.1 Formation of Dry Particles by Standard Methods 
a) Freeze-Drying and Pulverization 
Freeze drying is the method of choice to transfer a protein solution in the solid 
state. The lyophilization process can be divided into three steps: At first, the 
protein solution along with adequate excipients is frozen. During primary drying, 
the main amount of frozen water is removed by sublimation. In the following 
secondary drying associated water is removed to the desired residual moisture 
content under increased vacuum and elevated temperatures [Jennings, 1999]. 
The obtained lyophilisat, a dry and ideally fluffy cake, is then subjected to a 
milling or grinding process to obtain protein particles. Among the variety of mills, 
the jet-mill (fluid-energy mill) seems to be most suitable for size reduction of 
protein particles and aggregates [Maa et al., 2000]. In dependence of inlet fluid 
pressure, powder feed rate, bulk powder morphology, material hardness and 
starting size distribution, particles smaller than 5 µm can be achieved. As a rule 
of thumb, the smaller the desired particle size, the more energy is required for 
its pulverization. The energy input is partially transformed into heat. Stability 
problems may arise both from the thermal and mechanical stress during the 
milling process. Electrostatic charging of the processed particles is another 
problem. The main disadvantage of freeze drying lies in its expensiveness, as it 
is a time and energy consuming process. A broad size distribution with irregular 
shaped particles and poor particle size control further limit its rational 
application for particle formation. A novel approach based on co-lyophilization 
with PEG directly leads to the formation of spherical fine particles without the 
need of pulverization (see 1.2.3.5). The major disadvantage of this approach is 
the need of organic solvents for particle separation [Morita et al., 2000].  
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b) Spray (Freeze) Drying 
A well-established method for the preparation of particulate solids is spray 
drying [Lee, 2002]. Atomizing a liquid feed into a hot drying medium generates 
particles. The water of the feed fluid evaporates at once due to the tremendous 
surface increase by the atomizing process and the elevated temperatures of the 
drying medium, leaving alone the dried particle. Spray freeze drying combines 
the principles of classic spray drying and lyophilization. The protein solution is 
atomized in liquid nitrogen, where the formed droplets were frozen immediately. 
Subsequent lyophilization leads to dry particles. The rationale is to circumvent 
any possible thermal stress for the protein caused by accelerated drying 
temperatures in the classic spray drying procedure. Problematic in spray drying 
is the risk of surface denaturation. Spray freeze drying is a complex process, 
and the particle density control is poor.  
c) Supercritical Fluids (SCF) 
Above a critical temperature and a critical pressure, a fluid features unique 
physical properties [Winters et al., 1996]. Minor changes in the pressure can 
then be utilized to modulate these properties within the extremes of its liquid-like 
solvent power and its gas-like transport characteristics. For biopharmaceutical 
applications, CO2 is advantageous due to its mild critical temperature of 31.1°C, 
relative moderate critical pressure of 73.8 bars, non-toxicity and non-flam-
mability [Subramaniam et al., 1997]. In dependence of the solubility of the 
biomolecule in the SCF, it serves as an antisolvent or as a solvent. In the latter, 
rapid expansion of a supercritical fluid utilizing a nozzle or a capillary leads to 
supersaturation of the solute and subsequent to precipitation of pure solute 
particles. In the antisolvent technology, two process scenarios are thinkable: A 
classic solvent is required that serves as solvent for the protein and is miscible 
with the supercritical solvent. By simple mixing the solution with the supercritical 
phase, its solvation power is reduced and the protein is forced to precipitate or 
crystallize. Another possibility to generate particles with SCF is spraying the 
protein solution into supercritical carbon dioxide, a process termed ASES 
(Aerosol Solvent Extraction System). The handling of processes dealing with 
SCF is technically demanding. In addition, biomolecules generally feature 
limited solubility in SCF, and the process often requires organic solvents. 
The above-discussed methods all deliver dry particles, so that the development 
of an aqueous protein suspension will need additional operations. Difficulties 
may arise from undesired dissolution processes of the particles in the 
dispersion fluid. Furthermore, the above-mentioned techniques either mean 
stress to the biomolecule (heat denaturation, shear stress, surface denaturation, 
use of organic solvents), or the process is costly (requires expensive equip-
ment, time, energy). Therefore, the development of a cheap, easy performable 
procedure that does not harm the protein is challenging. Based on the limited 
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solubility of rhBMP-2 in water, classic precipitation in an aqueous environment 
might meet the criteria.  
1.2.2 Protein Precipitation: Definition and Principles 
In a comprehensive definition, precipitation can be described as a reduction of 
the solute solubility so that most of the solute molecules can no longer stay in 
solution [Maa et al., 2000]. Solubility of a protein in a solvent is determined by 
the complex interactions between the surface of a protein with a given solvent, 
the interactions between protein molecules as well as interactions between the 
solvent molecules [Rothstein, 1994]. The surface characteristics of a given 
protein are mainly determined by the properties of the amino acids building up 
the protein backbone and their distribution at the solvent accessible surface. 
Depending on the chemical structure of the amino acid side chain, they can be 
classified as hydrophobic (apolar aliphatic, heterocyclic or aromatic residues, 
e.g. Gly, Ala, Val, Leu, Ile, Met), hydrophilic (polar aliphatic residues, e.g. Ser, 
Thr, Cys, Asn, Gln) or ionisable (Asp, Glu, His, Lys, Arg) [Simpson, 2004a]. 
According to simplified basic thermodynamics, each system is seeking for 
minimal energy and a maximum of chaos. Therefore, a protein is soluble in a 
given solvent if the solvent-solute interactions are attractive, indicated by a 
negative free energy change, that more than compensates the sum of the free 
energy decrease caused by solvent-solvent and protein-protein interactions. 
Positive, i.e. repulsive protein-protein interactions further favor increased 
solubility. Otherwise, the protein is insoluble, resulting in crystallization or 
precipitation.  
1.2.3 Precipitation Methods 
Protein precipitation methods can be divided in physical methods (e.g. changes 
in temperature; changes in pressure (see 1.2.1); evaporation of solution) and 
methods based on the addition of reagents, either directly interacting with the 
solute or indirectly influencing its solubility by changing the characteristics of the 
solvent without dramatic changes in temperature and in the solute/solvent ratio 
[Fornasiero et al., 1999]. In principle, reversible and irreversible precipitation 
can be distinguished. In the latter, the protein structure is damaged or lost and 
cannot be restored. A lot of stresses can cause irreversible precipitation, the 
most prominent being temperature, pH and organic solvents [Scopes, 1995]. In 
this work, focus is laid on the methods leading to reversible precipitation by 
chemicals, although it must be pointed out that there is a smooth transition from 
reversible to irreversible precipitation in dependence of the applied conditions. 
One should consider that our knowledge about precipitation is still very 
empirical and the described theories and mechanisms are simplifications and 
serve as models to support our understanding of the complex process of 
precipitation. In reality, the itemized methods might influence and interact with 
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each other, and the adjustable parameters needed to be orchestrated for an 
optimized precipitation process.  
1.2.3.1 Crystallization 
Crystallization can be classified as a special form of precipitation. In simplified 
terms, protein crystals are generated from a concentrated protein solution under 
very specific conditions. Detrimental are the creation of a gradual supersatu-
rated solution and the maintenance of this non-equilibrium state during the 
crystallization process (Figure 1-5). 
 
Figure 1-5: Crystallization window of a hypothetical protein (adapted from Ducruix et 
al., 1990) 
Initially spontaneous formed nuclei act as crystallization centers for an ordered 
addition of macromolecules, thus forming new intermolecular contacts resulting 
in the crystal [Feher et al., 1985]. Insulin suspensions provide the most 
prominent example [Brange, 2000]. Also based on the concept of crystallization 
is the Crystalomics™ technology from Altus. In principle, a concentrated 
crystallization buffer is allowed to slowly equilibrate with the protein of interest 
by dialysis. Over time, the concentration of both the protein solution and the 
crystallization buffer rises, forcing the protein to crystallize or precipitate 
[Yakovlevsky et al., 2002]. Crystallization is a complex, time consuming and 
sensitive process, and scaling up might be difficult.  
1.2.3.2 Isoelectric Precipitation 
Protein solubility can be easily influenced by variation of the solution pH. A 
classic pH-solubility profile mimics the form of an asymmetric U. Therefore, by 
addition of either acid or base, a point can be adjusted where the solubility 
possesses a minimum (Figure 1-6).  
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Figure 1-6: pH-solubility profile and model illustration of isoelectric precipitation 
(adapted from Scopes, 1995) 
Due to its titratable groups, derived from the side chains of the amino acids and 
potentially associated sugars, biomolecules are polyampholytes, i.e. they carry 
both positive and negative charges in dependence of the solution pH. The pH at 
which the net charge of a given protein is zero defines its isoelectic point (pI). At 
this pH, electrostatic repulsive forces are minimized, the number of thermo-
dynamically favored interactions of charged entities with water as dipole is 
diminished, and hydrophobic forces dominate the solubility behavior. Hydro-
phobic patches on the surface of the protein coming in contact with water 
molecules force them to order. This process is termed hydrophobic hydration. 
The ordering is accompanied by a large decrease of entropy. This decrease, 
which is proportional to the surface area of the apolar entity, is correlated with a 
reduced solubility in water [Privalov et al., 1989]. Thus, apolar entities tend to 
avoid or at least minimize contact with water by reducing the exposed surface 
by self association. Additional charges can be introduced into a protein by salt 
specific ion binding. Anion binding can shift the pI of proteins to more acid 
values and therefore might increase the minimum solubility (salting-in). The 
binding of cations shifts the pI to higher pH values. Extremes of pH can have 
great impact on the charge distribution within a biomolecule, thus creating 
destructive repulsive forces or diminish initially stabilizing interactions within the 
protein structure. Such processes finally lead to irreversible precipitation.  
1.2.3.3 Salt-induced Precipitation: Salting-out 
The phenomenon of salting-out can be observed by the addition of high 
amounts of neutral salts to protein solutions. The nature of the salt has great 
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influence on its ability to precipitate proteins. Hofmeister, the name generator of 
the famous lyotropic series, first elucidated the relative effectiveness of neutral 
salts in salting-out proteins. For some common anions, the potency to salt-out 
proteins increases in the order thiocyanat < chlorate < nitrate < bromide < 
chloride < acetate < sulphate < phosphate < citrate. A minor contribution 
derives from the cations, with ammonium being most effective, followed by 
potassium and sodium [Hofmeister, 1888, Von Hippel et al., 1969]. Interestingly, 
the potential of the ions to stabilize the structure of a macromolecule parallels 
this series, with ions favoring precipitation act as stabilizers. The most 
frequently used and therefore the most prominent reagent for salting-out is 
ammonium sulphate. It unites a series of advantages (modified from Englard et 
al., 1990):  
• saturated solutions pose sufficiently high molarity to precipitate most 
proteins 
• marginal heat of solution allows addition to protein solution without the 
need to cool it 
• even saturated solutions pose a sufficiently low density not to interfere 
with precipitate recovery by centrifugation  
• preservative properties of concentrated solutions  
• protects most proteins from denaturation 
The required salting-out concentration depends on the nature of the salt and on 
characteristics of the protein. Size and shape of the protein are critical 
parameters. Irregular shaped proteins and proteins of higher molecular weight 
and otherwise similar features require smaller amounts for precipitation.  
The effect of salting-out is empirically linked to the ionic strength by the 
equation of Cohn [Edsall, 1947]. On a semi-logarithmic scale the solubility 
decreases linearly with increasing ionic strength of a concentrated salt solution:  
logS = β - KsI 
S solubility 
I ionic strength 
β, K constants 
The salting out constant Ks is specific for the protein and the salt employed. The 
constant β marks the hypothetical solubility at zero ionic strength (Figure 1-7) 
and is a function of temperature and pH, with a minimum at the isoelectric point 
[Bell et al., 1983]. This empirically found relationship is only true for 
concentrated salt solutions. Low concentrations of salts have a solubilizing 
effect for most proteins at and above its isoelectrical point [Rothstein, 1994], a 
process termed salting-in. 
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Melander and Horwarth provide a theoretical approach explaining the dual role 
of salt on the solubility of macromolecules [Melander et al., 1977]. It is based on 
the cavity model, which assumes that in a first step work is required to form a 
cavity in the solvent in which the solute can be introduced (?Gcavity) before the 
solute can interact with the solvent (?Ginteraction). The model also considers the 
decrease in entropy by the solute free volume change. According to their work, 
the observed solubility is the net result of both electrostatic and hydrophobic 
interactions (Figure 1-7). Salting-in, mainly determined by surface charge 
distribution and polar interactions, dominates at low ionic strength. At sufficient 
high salt concentrations, the specific interactions between electrolytes and 
proteins are masked, and the macromolecule effectively behaves as a neutral 
dipole. Then, the overall salting-out curve is dominated by hydrophobic 
interactions that now superimpose the still present solubilizing influence of 
electrostatic repulsion [Scopes, 1995].  
 
 
Figure 1-7: Schematic illustration of the overall salting out curve (solid) as the net 
result of electrostatic (dash dot) and hydrophobic (dashed) interactions 
(modified from Melander et al., 1977) 
The model character of this approach becomes apparent, as it fails to describe 
salt specific effects at low ionic strength. Up to now, a comprehensive theory is 
lacking.  
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1.2.3.4 Miscible Organic Solvent Precipitation 
With the exception of the prolamines, most proteins become rapidly insoluble 
with rising concentrations of organic solvents [Kistler et al., 1980]. A lot of 
different solvents have been utilized. Practical importance gained methanol, 
diethyl ether, acetone and ethanol, with the later being the reagent of choice 
due to a number of advantages: 
• melting point depression enables fractionation at subzero temperatures, 
thus minimizing denaturation  
• no generation of explosive gas mixtures under usual working conditions 
• low molecular weight 
• highly volatile 
• chemically relative inert 
• low toxicity 
• inexpensive and easily available 
• inhibition of bacterial growth 
The most prominent example utilizing ethanol is the fractionated precipitation of 
plasma proteins. Basically developed by Cohn and co-workers in the middle of 
the last century (1946), the procedure is still the basis for the production of the 
main plasma proteins [P.Kistler et al., 1980]. Plasma fractionation is performed 
according to the “five parameter system”: pH, ionic strength, protein concentra-
tion, organic solvent concentration and temperature. The latter should be held 
well below 0°C to minimize the denaturizing effect of the alcohol. At higher 
temperatures, the flexibility of a protein might be sufficient for small molecules 
entering the “interior”, interacting with hydrophobic residues usually buried 
within the molecule and therefore destabilizing it. 
The free energy of electrostatic interactions is linked to the inverse of the 
solvent dielectric constant. Therefore, the high dielectric constant of water is 
used to explain its solvating power for hydrophilic, charged proteins, with the 
free energy being minimal between the dipole water and the polar protein. 
Additional, hydrophilic solvation occurs in this system: water molecules form a 
hydration shell by the formation of a structured layer around the polar protein. 
The electric field of the ionic entity also affects the properties of water molecules 
beyond this layer ‘deeper’ in solution, building up the hydration zone. In a 
mechanical view, the hydration layer(s) acts as a physical spacer between the 
surrounded protein molecules, thus preventing them to come into contact and 
improving its solubility. The addition of an organic cosolvent to water decreases 
its solvation power, accompanied by a decrease of the dielectric constant. 
Another approach suggests a competitive process for the water molecules 
between the protein and the added alcohol to be responsible, leading to protein 
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dehydration at sufficiently high ‘cosolvent’ concentration (Figure 1-8). 
Electrostatic and dipolar forces are thought to be mainly responsible for 
subsequent aggregation. Hydrophobic forces seem to be less relevant due to 
the solubilizing influence of organic solvent on the hydrophobic patches. The 
removal of ordered structures of water molecules from such protein surfaces 
(hydrophobic hydration) and their replacement by the organic solvent provides 
an explanation for the increased solubility of hydrophobic proteins such as the 
prolamins in organic water mixtures [Kistler et al., 1980].  
 
Figure 1-8: Simplified illustration of the precipitation mechanism by organic solvents 
(modified from Scopes, 1995) 
Based on the precipitation power of organic solvents is the PCMC® technology 
(Protein-coated Microcrystal) from XstalBio. Drop wise addition of an aqueous 
solution containing the biomolecule and an inert crystal-forming coprecipitant 
into an organic solvent leads to non-covalently immobilization of the protein on 
the surface of the support material [Bechthold-Peters, 2003, Moore et al., 2000]. 
1.2.3.5 Precipitation by Non-ionic Polymers 
Dextrans, polyvinyl pyrrolidone, polypropylene glycol and polyethylene glycol 
(PEG) have found applications as non-ionic polymeric precipitating agents. PEG 
is most widely used due to the following advantageous properties (modified 
from Hao et al., 1980): 
• no interaction with proteins and no denaturing potential even at high 
concentrations 
• acceptable viscosity in solutions up to 20 % (w/v) with respect to 
recovery by centrifugation, compared to other non-ionic polymers 
hydrophobic patch 
organic solvent 
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• low heat of solution 
• precipitation behavior relative insensitive to minor changes in 
temperature 
• shorter equilibration time, compared with ethanol or ammonium sulphate 
It is generally accepted that non-ionic polymer induced protein precipitation is 
based on the concept of steric exclusion: in the three-component system water-
protein-PEG, the polymer is sterically excluded from the protein domain and 
therefore the protein is preferentially hydrated. By continuous addition of a 
polymer to a protein solution, the polymer occupies more and more volume of 
the solution. This forces the protein to concentrate in the extrapolymer space, 
and finally to precipitate [Atha et al., 1981]. As PEG is a polymer, different types 
varying in their molecular weight are available. Up to a limit of 6000 Da, the 
higher the molecular weight, the larger is the protein displacement. Species with 
higher molecular weight are considered to undergo chain folding and therefore 
did not further increase the excluded volume, but increase the viscosity. 
Consequently, PEG species in the range of 4000 - 6000 Da are preferred. A 
theoretical expression describing the precipitation of proteins by non-ionic 
polymers is provided by Juckes [Juckes, 1971]: 
log S = log S0 – KP [PEG] 
S solubility of protein 
S0 solubility of protein in absence of PEG 
KP constant 
[PEG] polyethylene glycol concentration 
KP is a linear function of the Stokes radius of the protein and the size of PEG up 
to 6000 Da, but relative independent from the solution conditions pH and ionic 
strength, which influences S0. The use of the term is limited to dilute protein 
concentrations, as it does not account for specific protein-protein interactions 
that occur at higher concentrations. The analogy of the equation to the 
expression used for salting-out should be mentioned (see 1.2.3.3).  
1.2.3.6 Precipitation by Metal Ions 
A number of polyvalent heavy metal ions have affinities to certain structures 
present in proteins and therefore can be used for protein precipitation (Table 
1-3). The great advantage of these reagents is that millimolar concentrations 
are sufficient. It is important to point out that minimal solubility is obtained at 
slightly higher pH-values than pI, however, basic milieu should be avoided to 
prevent formation of metal hydroxides [Rothstein, 1994].  
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Table 1-3: Affinities of cationic metal ions to certain structures (modified from Bell et 
al., 1983) 
cation preferred interaction with 
Ca2+, Pb2+, Ba2+, Mg2+ carboxyl groups 
Zn2+, Cu2+, Cd2+, Mn2+, Fe2+ 
Co2+, Ni2+ 
nitrogenous compounds: 
hererocycles, amines 
Hg2+, Ag+, Pb2+ sulfhydryl groups 
In general, two kinds of binding are suggested: the formation of a simple ion-ion 
complex and the combination of the metal ion with two or more ligands, building 
up a coordination complex [Gurd, 1954],[Bertini et al., 1995]. Dimer and 
hexamer formation by self association of insulin monomers in the presence of 
zink probably provides the most significant example in the pharmaceutical field 
[Brange, 2000]. It should be mentioned here that specific ion binding can be 
advantageous in combination with other precipitation techniques, e.g. Ca2+, 
Ba2+ and Zn2+ in ethanolic precipitation [Bell et al., 1983]. 
1.2.3.7 Protein Binding Dyes 
One example of this class has gained major attention for the fractionation of 
plasma proteins: the organic base rivanol (2-ethoxy-6,9-diamino acridine 
lactate) [Steinbuch, 1980]. The electrostatic rivanol-protein complex, which is 
formed at pH slightly above pI of the protein, is hydrophobic and precipitates. 
Other dyes with high binding capacities, used for selective protein purification 
from crude mixtures are described elsewhere [Niederauer et al., 1992]. 
1.2.3.8 Precipitation by Ionic (Poly)-Electrolytes  
Compared to the already described precipitation agents, ionic polyelectrolytes 
have received little attention, probably due to their tendency to damage protein 
structures [Simpson, 2004b]. Nevertheless, single candidates have shown to be 
useful and effective for specific separation tasks. Their advantage is cheapness 
and the lack of waste disposal problems, making them attractive in industrial 
applications. In addition, only concentrations between 0.05 and 0.1 % (w/v) are 
required. A classification with selected examples is given in Table 1-4. Also 
included are some acid precipitants which do not fit into the polyelectrolyte 
category, but were noteworthy to mention. Polyelectrolytes precipitate proteins 
with an opposite charge by complex formation, preferring molecules of higher 
charge density [Niederauer et al., 1992]. Suffice to say that variables that 
influence the charge, especially pH and ionic strength, greatly influence their 
precipitation behavior. In addition, the type, molecular weight and concentration 
of the polyelectrolyte on the one hand and size and surface characteristics of 
the target protein on the other are critical parameters.  
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Table 1-4: Selective polyionic precipitation agents (extracted and modified from 
Rothstein, 1994) 
 precipitation agents target protein(s) references 
Cationic precipitants 
protamines fibrinogen from plasma Mylon, 1942 
polyvinylamine bovine albumin Morawetz and Hughes, 1952 
natural and 
synthetic 
poly-
electrolytes polyethylenimines isolation of enzymes 
Boeringer 
Mannheim, 
1972 
Anionic precipitants 
short chain fatty 
acids: caprylic acid IgG 
Steinbruch et 
al., 1965 
TCA (trichloracetic 
acid) 
large scale separation 
from human albumin 
from placental blood 
Liautaud, 
1974 acids [small 
anions] 
perchloric acid, 
sulfosalicylic acid 
isolation of highly 
glycosylated, very 
soluble glycoprotein 
from plasma 
Winzler et al., 
1948 
sulfosalicylate, 
tungstate, 
metaphosphates, 
linear 
polyphosphates 
differential precipitation 
of serum proteins, 
plasma fractionation 
Astrup et al., 
1954, Berry et 
al., 1956, 
Nitschmann et 
al., 1959 
tannic acids 
isolation of glucose 
dehydrogenase from 
bacterial cultures 
Coulthard, 
1945 
heparin (in presence 
of MgCl2) 
lipoproteins  
(VLDL; LDL) 
Burnstein, 
1970 
natural 
anionic 
polymers 
chondroitin sulphate fibrinogen,  beta- lipoproteins 
Anderson, 
1963 
polyacrylic acid protein fractionation Weiland et. al., 1953 
carboxymethyl 
cellulose egg white protein 
Clark and 
Glatz, 1987 
polystyrene 
sulfonates 
albumin-gama globulin 
separation Isliker, 1957 
polysaccharides: 
polysulfuric acid fibrinogen from plasma 
Astrup and 
Piper, 1946 
dextran sulfates 
(of higher molecular 
weight) 
fibrinogen from plasma Walton, 1952 
synthetic 
anionic 
poly-
electrolytes 
sulphated 
amylopectin 
low-density lipoprotein 
precipitation Day, 1975 
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1.2.3.9 Affinity Precipitation 
This highly specific binding is based on the concept of complementary antigen-
antibody interaction between a target protein and a ligand. Complex formation 
will result in aggregation and precipitation. The affinity of lectins to glycol-
moieties of glycoproteins provides an example [Latner et al., 1980]. For a 
comprehensive review, see Hilbrig [Hilbrig et al., 2003]. The formation of 
insoluble protein-anion complexes at low ionic strength at pH values acid to the 
proteins isoelectric point is also considered to be an affinity precipitation 
mechanism.  
Particle stabilization by Cross-linking  
Cross-linking is a well known procedure for the stabilization of nanoparticles 
[Langer et al., 2003]. Woizwillo suggested cross-linking for the production and 
stabilization of precipitated macromolecules [Woiszwillo, 1994]. However, the 
covalent linkage of biomolecules is considered to be problematic with respect to 
bioactivity, immunogenicity and antigenicity.  
1.2.4 Precipitate Formation 
For the preparation of particles by precipitation, it is helpful to understand the 
underlying principles. Precipitate formation can be divided into 4 stages 
(modified from Rothstein, 1994 and Bell et al., 1983): 
Stage I: Nucleation and perikinetic growth 
Fundamental for precipitation is an initial supersaturated and therefore meta-
stabile state as driving force for nucleation and growth. These are energy 
consuming processes, as a more ordered structure of associated molecules 
compared to their random distribution in solution is created. Initially, submicron 
sized associations are generated on a molecular level based on diffusion, 
referred to as nucleation, and condensation of additional molecules to stable 
associates further increases their size. 
Stage II: Perikinetic association and aggregation 
Collisions of nuclei by diffusion and consequent adhesion to each other result in 
the formation of stable primary particles of colloidal size. 
Stage III: Ortokinetic growth 
Orthokinetic growth describes the growth and formation of a macroscopic visible 
precipitate composed of primary particles and nuclei condensed after collision 
caused by bulk movement (convective transport). In this stage, larger particles 
can also be subjected to breakup and erosion as a consequence of fluid shear 
forces. 
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StageIV: Protein aging 
During this phase, effects of overprecipitation are partially reversed by 
redissolution of proteins which are usually soluble under the given solution 
conditions. Furthermore, under appropriate shear, aggregates ‘mature’ in 
respect to size, strength, shape and density.  
1.2.5 Precipitation Process Conditions 
With the knowledge of the basics in precipitate formation, the influence of 
process parameters on the physical properties of the precipitate characteristics 
might become clear. The major concern in adjusting the system and operation 
variables is the avoidance of local excess concentrations of the precipitating 
agent in the protein solution, as this can cause overprecipitation, damage to the 
protein and the formation of highly solvated, small precipitates. For the 
conduction of a precipitation experiment, three components are required: a 
protein solution, a precipitating reagent and a reactor system: 
A parameter that is critical for all precipitation procedures is the initial protein 
concentration in the bulk solution. To achieve precipitation, a sufficiently high 
starting concentration is required which exceeds the benchmark of protein 
solubility under the chosen precipitation conditions. For the purification of 
protein mixtures, higher selectivity could be achieved from more diluted solu-
tions, with an increased amount of required precipitation agent as consequence.  
The choice of an appropriate reagent, its physical stage (solid vs. liquid), its 
concentration in stock solution, the rate of addition to the protein solution and 
the final concentration are important factors.  
The mode of operation (batch vs. continuous), the subsequent reactor design 
(tank geometry, agitator design and geometry, sparger design and geometry, 
use of static mixers) and the mixing mode (turbulent vs. laminar) have a great 
influence on the shear profile and therefore on the characteristics of the 
precipitate. It should be noted that turbulent mixing is advantageous to quickly 
achieve a homogeneous distribution, but bears the risk of particle breakage due 
to the shear stress. Some precipitation methods require the possibility to adjust 
and control the temperature (e.g. low temperatures required for ethanolic 
precipitation; removal of excess heat of dissolution caused by a precipitant). 
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2 Objectives of the Work 
The aim of the thesis was the development of an injectable, sustained release 
rhBMP-2 formulation, based on the concept of controlled precipitation to create 
protein particles. Furthermore, the potential of precipitation to generate highly 
concentrated formulations and the feasibility of precipitated protein as 
alternative storage form was to be evaluated. In this context, several aspects 
had to be addressed.  
- Development of a controlled precipitation process leading to an 
aqueous protein suspension of highly pure rhBMP-2 microparticles. 
The influence of process parameters on particle formation and 
distribution had to be evaluated. The parameters that allow controlling 
the particle size should be elucidated. The feasibility of the process 
for scaling-up should be investigated. 
- Optimization of the formulation composition. The influence of the 
formulation composition on particle size and the potential of selected 
excipients to control size and stability had to be tested.  
- For characterization of the formed microparticles, a suitable tool had 
to be established that allows sizing of small volumes of highly 
concentrated protein suspensions, and a method for visualization 
should be implemented. 
- The influence of precipitation on the native conformation of rhBMP-2 
should be analyzed, and the secondary structure in the precipitated 
state had to be elucidated. Bioactivity testing of precipitated material 
should be performed in cell culture. 
- The potential of precipitation to prevent chemical and physical 
instabilities had to be evaluated and compared with the commercial 
available formulation, and storage conditions had to be defined 
allowing sufficient shelf life.  
- Establishment of an in vitro release assay for the microparticle 
suspension using serum and evaluation of the release profile. The 
feasibility of the formulation to accelerate bone formation had to be 
tested in vivo in an animal model. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 rhBMP-2 
Recombinant human bone morphogenetic protein-2 (rhBMP-2), expressed in a 
genetically engineered Chinese hamster ovary cell line was provided by Wyeth 
BioPharma, Andover MA, U.S.A. The protein was delivered in a bulk 
concentration of 4-6 mg/ml, formulated in a buffer pH 4.5 containing 5 mM 
L-glutamic acid, 2.5 % L-glycine, 0.5 % sucrose, 5 mM NaCL and 0.01 % 
polysorbate 80 (referred to formulation buffer) and was stored frozen at -80°C 
until use. 
3.1.2 Reagents and Substances 
reagent description supplier 
acetonitrile HPLC gradient grade Merck  
(Darmstadt, Germany) 
purified water freshly prepared with 
a PureLab Plus™ 
purification system 
ELGA LabWater  
(High Wycombe, Buckings, 
UK) 
CaCl2 * 2 H2O p.a. Merck  
(Darmstadt, Germany) 
Collodial Blue staining 
kit 
composed of stainer 
A and B 
Invitrogen GmbH 
(Karlsruhe, Germany) 
chondroitinsulfate  Symatese Biomatériaux 
(Chaponost, France) 
dithiothreitol (DTT)  Aldrich-Chemie (Steinheim, 
Germany) 
EDTA * 2 H2O, 
disodium salt 
≥ 99.9 % Sigma  
(Steinheim, Germany) 
Endoproteinase Asp-N sequencing grade Roche Diagnostics 
(Mannheim, Germany) 
ethylene glycol purissimum Fluka (Buchs, Switzerland) 
gelatin type B, from bovine Sigma  
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reagent description supplier 
skin, 75 bloom (Steinheim, Germany) 
glacial acetic acid pure in-house supply 
glycine ≥ 99 % Sigma  
(Steinheim, Germany 
guanidine * HCl ≥ 98 % Fluka (Buchs, Switzerland) 
HCl 1 N solution p. a. Merck  
(Darmstadt, Germany) 
heptafluorobutyric acid purris. p.a. Fluka (Buchs, Switzerland) 
hyaluronic acid 1 % solution Fidia (Munich, Germany) 
iodoacetic acid, 
sodium salt 
99 % Aldrich-Chemie (Steinheim, 
Germany) 
KCl p.a. Merck  
(Darmstadt, Germany) 
KH2PO4 p.a. Fluka (Buchs, Switzerland) 
KOH 0.1 N solution Merck  
(Darmstadt, Germany) 
KOH flakes, p.a. Merck  
(Darmstadt, Germany) 
L-arginine * HCl extra pure Merck  
(Darmstadt, Germany) 
L-glutamic acid 99-100 % Sigma  
(Steinheim, Germany) 
L-glycine p.a. Sigma  
(Steinheim, Germany) 
L-histidine 98 % Aldrich-Chemie (Steinheim, 
Germany) 
Mark12™ unstained markers 
(2.5 – 200 kDa) 
Invitrogen  
(Karlsruhe, Germany) 
methanol gradient grade Merck  
(Darmstadt, Germany) 
Na2HPO4 * 2 H2O p. a. Fluka (Buchs, Switzerland) 
Na2SO3 anhydrous, p.a. Sigma  
(Steinheim, Germany) 
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reagent description supplier 
NaCl p.a. Fluka (Buchs, Switzerland) 
NaOH 1 N solution p. a. Merck  
(Darmstadt, Germany) 
NuPAGE®LDS Sample 
Buffer 
containing glycerol, 
Tris Base, Tris HCl, 
LDS, EDTA, Serva 
Blue 250, Phenol 
Red, ultrapure water 
Invitrogen  
(Karlsruhe, Germany) 
NuPage®MOPS SDS 
running buffer 
containing MOPS, 
Tris Base, SDS, 
EDTA 
Invitrogen  
(Karlsruhe, Germany) 
NuPAGE® Reducing 
Agent 
0.5 M DTT Invitrogen  
(Karlsruhe, Germany) 
poloxamer Lutrol®F68 BASF  
(Ludwigshafen, Germany) 
polysorbate 80 Crillet HP4, high 
purity 
Croda  
(Nettetal, Germany) 
Povidone K 90 Kollidon 90F, Ph. Eur, 
USP, JP 
BASF  
(Ludwigshafen, Germany) 
SilverExpress® 
staining kit 
composed of sen-
sitizer, stainer A/ B,  
developer, stopper 
Invitrogen  
(Karlsruhe, Germany) 
sodium alginate  Fluka (Buchs, Switzerland) 
sodium azide purum, p.a. >99 % Fluka (Buchs, Switzerland) 
sucrose p.a. Sigma  
(Steinheim, Germany) 
trifluoroacetic acid for spectroscopy Merck  
(Darmstadt,  Germany) 
Trizma® base reagent grade Sigma  
(Steinheim, Germany) 
urea > 99.5 % Fluka (Buchs, Switzerland) 
CaCl2 p.a. Merck  
(Darmstadt, Germany) 
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Serum was prepared from fresh human blood (3*50 ml) which was allowed to 
coagulate for approx. 1 hour at room temperature. The tubes were centrifuged 
for 40 minutes at 4410 RPM with a Universal 16R centrifuge (Hettich GmbH, 
Tuttlingen, Germany). The supernatant was collected and frozen at -20°C. For 
the in vitro release studies, the serum was preserved with 0.02 % sodium azide. 
3.2 Methods 
3.2.1 Focus on the Protein 
3.2.1.1 Dialysis of Bulk Formulation 
For buffer exchange, rhBMP-2 was dialyzed against 1 mM HCl using a 
Spectra/Por®7 membrane with a molecular weight cut-off (MWCO) of 3.000 
(Spectrum Medical Industries Inc., Los Angeles, CA, U.S.A.). After intense 
rinsing of the membrane with demineralized water, up to 10 ml rhBMP-2 were 
loaded into the membrane tube of appropriate length, closed with clamps and 
placed into the dialyse fluid, with a bulk to buffer ratio of 1:100-200. For the first 
4h dialysis was performed at room temperature, than at 2-8°C, with buffer 
exchange after 4 and 12 hours. After 24 hours under gentle stirring, the dialyzed 
protein solution was recovered, sterile filtrated through a 0.22 µm Minisart® filter 
(Sartorius AG, Goettingen, Germany) and aliquots were frozen at -80°C until 
use. 
For protein preparation of the microparticles used in the animal study, dialysis 
was performed in a sterile, ready to use Slide-A-Lyzer® (Pierce, Rockford, IL, 
U.S.A.) with a MWCO of 10.000 and a dialysis volume capacity of 3-12 ml. The 
dialysis fluid was exchanged for three times within a period of 42 hours at 2-8°C 
under gentle stirring.  
3.2.1.2 Ultrafiltration 
For concentration of diluted samples (for ATR-FTIR) or for buffer exchange of 
small sample volumes (<500 µl, for DSC measurements), centrifugation was 
employed, using Biomax Ultrafree® 0.5 centrifugal filters and tubes (10.000 
MWCO, Millipore Corporation, Bredford, MA, U.S.A.). Repeated runs at 4°C at 
10.000 G for 5 minutes were performed until the desired residual volume was 
achieved. For buffer exchange, 500 µl sample were centrifuged for 15 min 
(10.000 G/4°C), the retentate was diluted with the appropriate buffer to 500 µl 
and the procedure was repeated twice. 
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3.2.1.3 Concentration Determination 
3.2.1.3.1 UV 
For quantitative analysis of rhBMP-2, samples were measured spectroscopic-
ally at 280 nm in a Thermo Spectonic UV1 (Thermo Spectronic, Rochester, NY, 
U.S.A.). Results were corrected for basic absorbance of the solution at 320 nm. 
Protein concentrations [mg/ml] were calculated via the following equation:  
[rhBMP-2] = [(Absorbance sample 280/320 nm) – (Absorbance buffer 280/320 nm)] / 
1.43 
3.2.1.3.2 RP-HPLC 
Separation from other components and quantification of rhBMP-2 by reversed 
phase high performance liquid chromatography was performed on a VYDAC 
protein C4 column (4.6 mm x 50 mm, 300 Å, 5 µm particle size; VYDAC, 
Hesperia, CA, USA). The standard run used a water-acetonitril gradient 
containing 0.1 % trifluoroacetic acid from 0 to 80 % acetonitril. At a flow rate of 
3 ml/min, an injection volume of 50 µl was analyzed within 5 minutes. For 
improved separation from serum, the gradient was modified, ranging from 0-
100 % acetonitrile, and the flow rate was reduced to 2 ml/min. Detection of 
rhBMP-2 was performed at 214 and 280 nm [Duggirala 1996]. The analysis was 
carried out on a Hewlett-Packard HP Series 1100 instrument, comprising a 
degasser, a quaternary pump, a thermostatted autosampler and a diode array 
detector. The system was operated with ChemStation V6.0 software. 
3.2.1.4 High Molecular Weight Species and Aggregation 
3.2.1.4.1 SEC 
SEC was performed on a Spectra HPLC system consisting of a P 4000 
quaternary pump, AS 1000 autosampler and FL 3000 fluorescence detector 
(Thermo Separation Products GmbH, Darmstadt, Germany) or a Hitachi-Merck 
L-6200/L-4000 HPLC system equipped with fluorescence detector and a D 
2500 manual integrator (Hitachi Ltd, Tokyo, Japan). Samples were analyzed 
with a TSK-Gel®2000WXL column (7.8 mm x 30.0 cm, 5 µm particle size; Toso 
Haas, Japan) and isocratic elution with a 0.4 M L-arginine*HCl/5 mM glutamic 
acid buffer pH 4.5 at a flow rate of 0.6 ml/min. Controlling of the Spectra HPLC 
System and subsequent analysis was performed with ChromQuest® software.  
3.2.1.4.2 SDS-PAGE 
Gel electrophoresis was carried out in a XCell SureLock Mini-Cell electro-
phoresis chamber on NuPAGE® Novex Bis-Tris pre-cast gels (12 %, 10 wells, 1 
mm) and NuPAGE® MOPS SDS running buffer (Invitrogen GmbH, Karlsruhe, 
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Germany). According to the vendors instructions, non-reduced samples were 
prepared with 25 % of the NuPAGE® LDS sample buffer; reduced samples 
additionally contained 10 % NuPAGE® reducing agent. After heating for 10 
minutes at approx. 90°C and centrifugation, 20 µl typically containing 1 µg 
rhBMP-2 were loaded per lane. The loading volume of the Mark12™ unstained 
marker (1:10 diluted for silver stained gels) was 10 µl. Gels were run with a 
constant current of 0.04 A per gel for 2-3 hours. Silver staining was performed 
with the SilverExpress® staining kit according to the vendor’s protocol: Fixation 
in a methanol/acetic acid/water mixture, followed by the steps sensitizing, 
washing, staining, washing, developing, stopping and final washing. Coomassie 
staining (Collodial Blue staining kit) was carried out in two steps. Staining in a 
methanol/water/stainer mixture (55 % water, 20 % methanol, 5 % stainer A and 
20 ml stainer B) for 3 to 12 hours was followed by a de-staining and washing 
step in deionised water for at least 7 hours. After drying, analysis of the stained 
gels was performed by densitometry, using an Epson GT 9600 scanner and 
ScanPack 3.0 software (Biometra GmbH, Göttingen, Germany). 
3.2.1.5 Monitoring of Oxidation and Isomerization 
3.2.1.6 Peptide Mapping 
Samples were desalted on two 5 ml HiTrap™ desalting columns operated in 
series (Amersham Biosciences Europe GmbH, Freiburg, Germany), connected 
to a Merck-Hitachi L-6200/L-4000 HPLC system equipped with a D 2500 
integrator (Hitachi Ltd, Tokyo, Japan). Samples containing 50 µg protein were 
digested with 0.5 µg Endoproteinase Asp-N for 1.5 h at 37°C. Separation was 
achieved with a TSK Super-ODS 4.6 mm ID x 10.0 cm (Toso Haas, Japan) on a 
Agilent HP1100 HPLC system (Agilent Technologies Deutschland GmbH, 
Waldbronn, Germany) with UV detection at 214 nm. Met371 oxidation and the 
amount of isomerized Asp335 were calculated according to the following 
equations (Figure 3-1): 
Met371ox  = peak Aox * 100 / (peak A + peak Aox) [%] 
Asp335iso = peak ABiso * 100 / (peak ABiso + peak A + peak B + peak Aox) [%] 
 peak A  = peak area of peak A 
 peak Aox     = peak area of peak Aox 
 peak B = peak area of peak B 
 peak ABiso = peak area of peak ABiso 
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Figure 3-1: representative peptide map chromatograms of native standard (solid) and 
a degraded (dotted) sample 
3.2.1.7 Proteins’ Secondary Structure Integrity 
3.2.1.8 Differential Scanning Calorimetry 
Measurements were conducted with the Nano II Differential Scanning 
Calorimeter 6100 (Calorimetry Sciences Corp; Lindon, UT, USA). Data 
acquisition was performed from 25 to 110°C with a heating/cooling rate of 
1°C/min (n = 2). Analysis was performed utilizing the Cpconvert program of the 
instruments analysis software, assuming a two state process for the transition. 
Samples and background solutions were prepared either by dialysis or 
centrifugal filter devices. The concentrations were adjusted to 2.0 mg/ml by 
dilution with the appropriate buffer. The buffer exchange medium of the last 
dialysis step serves as background.  
3.2.1.9 (ATR) FT-IR Measurements 
Measurements were conducted with the Confocheck™ (Bruker Optik GmbH, 
Ettlingen, Germany) at a constant temperature of 25°C, an acquisition time of 
30 seconds and a resolution of 4 cm-1. For transmission measurements the 
Confocheck™ was equipped with the AquaSpec™ flowthrough transmission 
cell (6 µm path length, 1 µl sample volume), for ATR measurements the 
BioATRII™ cell (with silicon crystal, 10 µl sample volume) was used. 
Temperature dependent spectra were acquired from 25 - 94°C in steps of 3°C 
at an effective heating rate of approx. 0.7°C/min. Data were analyzed with the 
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OPUS™ software. Quantification of secondary structure elements was 
performed by comparison of the native transmission protein spectra with a 
protein transmission spectra library, using a partial least squares algorithm. 
Origin®7.0 software was used to obtain the point of inflection (applying a 
sigmoid fit according to the Boltzmann model and subsequent differentiation of 
the fitted curve). The concentrations of the samples vary within 10 - 20 mg/ml. 
Protein-free reference material was obtained by ultrafiltration. 
3.2.2 Focus on the Formulation 
3.2.2.1 Preparation Methods 
3.2.2.1.1 Turbulent Mixing: Vortex 
Precipitation was achieved by adding the precipitating reagent(s) in form of a 
solution, the so called precipitation solution, to the protein solution. Mixing of the 
precipitation solution with the protein solution was performed with the help of a 
Vortex Genie®2 (Scientific Industries, Bohemia, NY, U.S.A.) tuned on half-
maximum. In general, the test tube was filled with the appropriate volume of 
protein solution and the adequate volume of the precipitation solution was 
added with a manual pipette. Employed mixing ratios were 10+1, 9+1 to 1+1, 
and final suspension volumes of 1 to 33 ml were targeted. The standard proce-
dure for microparticle preparation has turned out to be the combination of equal 
volumes of rhBMP-2 (c = 2 mg/ml in 1 mM HCl) with 2 x phosphate buffer pH 
7.4 (2 x 50 mM, ionic strength 2 x 154 mM, adjusted with KCl).  
For the evaluation of excipients, 1+1 mixtures were performed with a final 
sample volume of 500 µl and a protein concentration of 1 mg/ml. The excipient 
was added together with the precipitation solution to the protein solution.  
For the incorporation of the microparticles in gel-like formulation, gels were 
prepared by mixing adequate amounts (w/v) of PVP with phosphate buffer (pH 
7.4, 50 mM) and allowed to swell overnight. Microparticles were prepared 
according to the standard procedure (see above), concentrated by removal of 
the half supernatant volume and combined with the prepared gels in 1.5 ml 
glass vials with the help of a stir bar. 
3.2.2.1.2 Laminar Mixing: Micromixer 
The micromixer® (Institut für Microtechnik Mainz GmbH, Mainz-Hechtsheim, 
Germany) was equipped with a nickel on copper inlay (10 µm channel width, 
25 µm channel depth) or a silizium inlay (30 µm x 100 µm). Feeding of the 
micromixer® was either performed with two syringe drivers (Perfusor®, Braun 
Medicare GmbH & Co KG, Melsungen, Germany) connected to the device with 
plastic tubes or two HPLC pumps (Hitachi-Merck L 6200, Waters type 590 
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(Waters Corporation, Milford MA, U.S.A.). In the HPLC approach, a rheodyne® 
valve (Rheodyne Europe GmbH, Bensheim, Germany) in combination with a 
500 µl sample loop was used to introduce small volumes of protein solution into 
the mixing process.  
3.2.2.1.3 Storage Stability Sample Preparation 
The reference formulations were prepared by dilution of protein bulk solution 
with appropriate volumes of formulation buffer (see 3.1.1) to a target concen-
tration of 2.5 mg/ml. The reference formulations intended to stay liquid were 
additionally preserved with 0.2 % sodium azide. 400 µl were filled into 2R vials. 
Precipitation was performed in 50 ml tubes by adding 10 x 1 ml dialyzed protein 
solution (c = 2.0 mg/ml) to (i) 10 ml preserved and (ii) 10 ml unpreserved 
phosphate buffer solution pH 4.5 (composed of 1.833 g KCl, 6.805 g KH2PO4, 
titrated with KOH to a pH of 7.4 and filled up to a volume of 500 ml). The 50 ml 
tube was vortexed before, during and after the addition. After an equilibration 
time of one hour, the microparticles were resuspended, and 1 ml aliquots were 
filled in 2R vials. Subsequently, the precipitate was concentrated at the bottom 
of the vial by centrifugation at 2550 RPM for 10 minutes, and 900 µl 
supernatant was removed. All vials containing no preservative were freeze-
dried according to 3.2.2.2.2. The preserved formulations, both precipitated and 
liquid were directly closed with stoppers, flanged and placed into storage. 
3.2.2.2 Additional Operations 
3.2.2.2.1 Centrifugation 
For concentration of the microparticle suspension, for preparation of storage 
stability samples and for the ultrafiltration experiments with centrifugal filter 
devices, either a Universal 16R centrifuge (Hettich GmbH, Tuttlingen, Germany) 
or a Sigma 4K15 (Christ, Osterode, Germany) was used.  
3.2.2.2.2 Lyophilization 
Already frozen samples (pre-treated with liquid nitrogen) were lyophilized with 
the program given in Table 3-1, performed with a Delta 1-24 KD Model freeze-
dryer (Christ, Osterode, Germany). 
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Table 3-1: Lyophilization cycle for already frozen samples  
step and time temperature [°C] vacuum [mbar] 
start 0 - 
ramp within 20 min -30 1 
hold for 40 h -30 1 
ramp within 2 h 20 0.04 
hold for 5 h 20 0.04 
 
For the samples of the stability study, lyophilization was performed with a Christ 
LPC-16/NT Epsilon 2-12 D (Christ GmbH, Osterode, Germany) according to the 
program given in Table 3-2: 
Table 3-2: Lyophilization cycle for samples of stability study 
step and time temperature [°C] vacuum [mbar] 
start 20 - 
ramp within 45 min -45 - 
hold for 90 min -45 - 
ramp within 16 min -30 0.1 
hold for 20 h -30 0.1 
ramp within 2 h 20 0.001 
hold for 4 h 20 0.001 
3.2.2.2.3 Viscosity Determination 
Viscosity was measured with a PaarPhysica MCR 100 (PaarPhysica; Ostfildern, 
Germany) equipped with a cone plate CP 50-1 at 25°C. The shear rate was 
modified according to the following program to reveal structural behavior of the 
gel: Within 3 min from 0-500 sec-1, holding at 500 sec-1 for 3 min, decreasing 
the shear rate from 500-0 sec-1 in 3 min. The viscosity at a shear rate of 
141 sec-1 was taken to characterize the gels. 
3.2.3 Particle Characterization 
3.2.3.1 Photon Correlation Spectroscopy 
PCS, also referred to as dynamic light scattering utilizes the random movement 
due to Brownian Motion of suspended particles to characterize them. As the 
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pace of the movement is inversely proportional to particle size, the analysis of 
the time dependency of the light intensity fluctuations scattered from the 
illuminated particles can be used to determine the size. Measurements were 
conducted with the ZetaPlus® Bi-MAS (Brookhaven Instruments Corporation, 
Holtsville, NY, U.S.A.). All solutions were filtrated through a 0.22 µm Minisart® 
(Sartorius AG, Goettingen, Germany) prior use for sample preparation.  
3.2.3.2 Laser Light Diffraction 
Measurements were conducted with a Mastersizer® X (Malvern Instruments Ltd, 
Worcestershire, UK) in a modified sample cell. The required sample volume 
was minimized by omitting the dispersion unit typically used for measurements. 
To further reduce the dead volume within the sample cell, inert teflon inlays 
were prepared an inserted, allowing measurements of sample volumes < 5 ml. 
After background alignment with protein free buffer, the protein suspension was 
measured. Therefore, it was directly filled into the modified sample cell, the 
whole cell was shaken manually, installed and the measurement was started 
after a delay of one minute to allow air bubbles to pass off. Laser light intensity 
was evaluated by Fraunhofer analysis underlying a polydisperse model. 
3.2.3.3 Light Microscopy 
Microparticles were visualized with a binocular microscope (Axiovert 25, Zeiss, 
Goettingen, Germany) under phase contrast, using a Ph1-0.4 filter. 3-5 µl were 
dropped on an object holder covered with a slip and examined under 20 fold 
magnification. Digital imaging of microparticles was done with a Sony Cyber-
shot DSC S75 (Sony GmbH, Cologne, Germany) connected to the microscope. 
3.2.3.4 Laser Light Blockade 
Laser light blockade measurements were performed with a Pamas®SVSS 
(Pamas, Rutesheim, Germany). Measurements were performed in triplicate and 
consumed a total suspension volume of 900 µl. Results were presented in 
number distributions. 
3.2.3.5 Environmental Scanning Electron Microscopy  
Environmental scanning electron microscopy (ESEM) was conducted at the 
FAU-Erlangen/Nuremberg, Department of Material Science, Glass and 
Ceramics with a Philips XL30 ESEM equipped with a gaseous secondary 
electron detector and operated in the low vacuum mode. 
For SEM, samples were carbon-coated by burning up a graphite-twine with a 
BAL-TEC MED 020 (Baltec AG, Balzers, Liechtenstein) with a maximum current 
of 125A, and examined with a JEOL Field Emission Scanning Electronic 
Microscope JSM-6500F(JEOL USA, Peabody MA, U.S.A.).  
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3.2.4 In-vitro Release 
In-vitro release of rhBMP-2 from microparticles was tested in serum containing 
0.02 % sodium azide. The microparticle suspension was combined with the 
serum in 2 ml pastic test tubes and placed in a Julabo SW21 shaking water 
bath (Labortechnik GmbH, Seelbach, Germany) at 37°C/50 RPM. At designated 
time points, either serum exchange was performed or the tube was finally 
sampled.  
3.2.5 Bioactivity Testing 
3.2.5.1 Determination of Bioactivity in Cell Culture 
The bioassay was performed at Wyeth BioPharma (Andover MA, U.S.A.). The 
target cell line W-20 clone 17, a bone marrow derived stromal cell line of the 
mouse, exhibits increased alkaline phosphatase activity in response to rhBMP2. 
Cells were grown in DME (Dulbecco’s modified Eagle’s medium) supplemented 
with FBS (fetal bovine serum) in flasks until a confluent cell layer developed. 
After harvesting, cells were seeded in a 96-well, flat-bottomed plate and 
incubated at 37°C overnight in a fully humified 0.5 % CO2 incubator. Samples 
and controls, diluted with assay medium to encompass the working range of the 
standard, were added. Each plate includes all the standard curve points, media 
controls, internal controls and test samples. After a second incubation of the 
treated cells for 24 hours, the assay medium was removed from the plates and 
the target enzyme alkaline phosphatase was liberated by lysis of the cells by a 
repeated freeze-thaw cycle. The substrate, p-nitrophenyl phosphate, was added 
to the well plate and developed while shaken gently. Absorbance values were 
read at 405 nm after stopping the reaction with diluted NaOH. Bioactivity was 
calculated from the reference standard curve using a four-parameter logistical 
fit. 
3.2.5.2 Efficacy Study in an Animal Model 
Surgical Procedure 
The efficacy study was conducted at Wyeth Research (Cambridge MA, U.S.A.). 
It involves four skeletally mature New Zealand White rabbits, treated in a 
unilaterally regimen with the precipitated microparticle suspension. The animals 
were pre-treated with an antibiotic and an analgesic (Table 3-3). Approximately 
twenty minutes before anesthetic induction, the animals received medication for 
muscle relaxation and general anesthesia. Corneal dryness was prevented by 
application of a bland ophthalmic ointment to both eyes. After shaving, the skin 
was disinfected with betadine solution and 70 % ethanol. After sedation and 
preparation, general anesthesia by halothane was administered via face mask. 
Intraosseous injection of the microparticle suspension was performed with a 
18-gauge needle under fluoroscopic guidance. The needle was positioned and 
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inserted into the distal femur through the lateral cortex with a slow rotation until 
the end was visualized in the region of interest in the intercondylar region of the 
epiphysis. After flushing the needle with 0.1 to 0.2 ml sterile saline, 300 µl 
rhBMP-2 microparticles wee injected. To minimize leakage out of the bone, the 
needle was held in place for at least one minute after the injection and pressure 
was applied to the injection site before the needle was taken out. For 
flourochrome labeling, tetracycline and calcein was administered as given in 
Table 3-3. After four weeks, the animals were sacrificed and examined.  
Table 3-3: Medication administered by injection 
time of application substance dose [mg/kg] route 
before surgery, after 1d cefazolin 10 SQ 
before surgery, after 1d buprenorphine 0.03 SQ 
before surgery ketamine 35 IM 
before surgery xylazine 5 IM 
10 and 25d post surgery tetracycline 25 SQ 
15 and 25d post surgery calcein 5 SQ 
 
Evaluation 
Radiographs were taken post-op and every two weeks in lateral position. For 
histology, the distal femur was isolated and undecalcified specimens were 
dehydrated with gradients of ethanol (70-100 %) and cleared in xylene using the 
LX120 Automatic Tissue Processor. Infiltration and embedding was done in 
methyl metacrylate which was allowed to polymerize for 3-5 days at room 
temperature. Blocks were cut at 10 µm using a Riechert-Jung Polycut or a Lecia 
2065 Supercut. Sections were stretched and pressed on gelatin-coated slides 
and tissue adherence to the slides was ensured by overnight storage at approx. 
50°C. After equilibration to room temperature, standard VonKossa staining was 
performed, followed by quantitative histomorphometry with a digitizing image 
analysis system (NIH Image software). 
 
 45 
4 Results and Discussion 
4.1 Formulation Development  
Researchers developing formulations for rhBMP-2 were often confronted with 
the phenomenon of macroscopic precipitation [Friess, 2000]. As this is usually 
considered to be an undesired instability criterion [Wang, 1999] efforts were 
made to avoid this. The rationale of this formulation approach is to utilize the 
high tendency of rhBMP-2 to precipitate for the generation of highly pure 
rhBMP-2 microparticles. In general, protein precipitates feature broad particle 
distributions with poor uniformity [Maa et al., 2000], and therefore are usually 
intermediate products during purification or concentration. In this work, a 
precipitation method should be developed leading to uniform microparticles, and 
the parameters determining particle size and distribution should be evaluated.  
4.1.1 Initial Precipitation Process Development  
4.1.1.1 Considerations and Setup 
As described in the theoretical part, three main categories - process technology, 
precipitation solution and protein solution - are the determining variables in a 
precipitation experiment. To keep the process quite simple, the combination of a 
precipitation solution with the protein solution is initially performed in a batch 
mode, using a manual pipette for liquid addition and a classic vortex for rapid 
and homogenous mixing of the two fluids (Figure 4-1). The batch volume is set 
to be 5.5 ml, adapted to the requirements of a modified particle size measure-
ment setup (see 3.2.3.2). A mixing ratio of 10 + 1 is chosen, leading to a total of 
5 ml protein solution pH 4.5 and 0.5 ml precipitation solution. 
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Figure 4-1: Scheme of initial process setup: the precipitation solution is quickly added 
to the already turbulent protein solution, and vortexing is continued for 
10 seconds 
The idea for the novel formulation is to utilize the low solubility of BMP under 
physiologic conditions [Abbatiello et al., 1997] for its controlled precipitation. 
Consequently, blood fluid serves as a template (Table 4-1) [Thews et al., 2004], 
with focus on the anion composition to mimic physiologic properties. The 
amount of base to adjust the pH to 7.4 is determined experimentally by titration 
(Figure 4-2). Finally, the precipitation solution contains the adequate salt 
concentrations (275 µl of a 20x stock solution), the desired amount of sodium 
hydroxide to achieve physiologic pH of 7.4 (20 µl 1M NaOH) and purified water 
(to adjust the precipitation solution volume to 500 µl). Based on a 10 + 1 mixing 
ratio and a final volume of 5.5 ml after mixing, a final protein concentration of 
0.18 mg/ml has proven to be suitable to allow direct laser light diffraction 
measurements of the precipitate without the need to dilute or concentrate the 
protein suspension altering the environmental conditions.  
  mixing by vortex 
addition of 
precipitation 
solution with 
pipette 
tube with 
protein solution
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Figure 4-2: Titration of a mixture of 5 ml pure protein formulation buffer, 275 µl salt 
stock solution (20 x) and 225 µl purified water with 1 M NaOH  
Table 4-1: Electrolyte-concentrations in blood fluid: the precipitation solution contains 
the grey underlined anions as sodium salts, resulting in the listed 
concentrations after mixing with the protein solution 
ion concentration [mmol/l] 
sodium 142 
potassium 5 
calcium 2.5 
magnesium 1 
chloride 102 
bicarbonate 27 
phosphate 1 
sulphate 0.5 
organic acids and proteins 7 
4.1.1.2 Particle Size Distribution of Initial Formulation  
Particle formation is a time dependent process. Initially, broad monomodal 
distributions are found, with maxima between 5 – 10 µm (Figure 4-3). In some 
experiments, an additional, very small population with a particle size below 
1 µm is present. 
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Figure 4-3: Initial particle size distributions of three different batches  
Over time, a second population develops leading to a bimodal distribution with 
two maxima at approx. 7 and 35 µm at equilibrium (Figure 4-4). In some 
batches, the small population below 1 µm is still present. The ratio of the two 
dominating maxima slightly varies in dependence of the shear force applied by 
the manual shaking procedure preceding each measurement.  
 
Figure 4-4: Particle size distributions of three batches after turbulent mixing and 
equilibration at room temperature  
The results demonstrate that the precipitation conditions are suitable to create 
microparticles. The distributions are in good agreement with theory. The small 
particle fraction at approx. 0.5 µm reflects the remnants of the primary particles 
formed in the perikinetic association and aggregation phase. Glatz postulates a 
primary particle size of 0.1 to 0.2 µm to be typical for proteins and sizes of 10 to 
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20 µm after flocculation [Glatz, 1992]. Isoelectric precipitated soy protein and 
casein led to basic particles of approximately 1 µm [Hoare, 1982, Bell et al., 
1982], being in good correlation to our findings. Further association of these 
submicron-sized particles can be classed to the ortokinetic growth phase, 
leading to microparticles with a preferred average size of approx. 7 µm. The 
transition from the ortokinetic growth phase to the protein aging phase is 
reflected by the formation of the second maximum, resulting in the bimodal 
equilibrium distribution. The observation of an equilibrium balance within the 
bimodal distribution and its sensitivity to shear forces suggests that the 
microparticle fraction of 35 µm consists of microparticles which are loosely 
associated with each other. With a residual solubility of 39±3 µg/ml (n=3) and a 
final protein concentration of 0.18 mg/ml after mixing, almost 80 % of the 
deployed protein form microparticles. 
4.1.1.3 Effect of Centrifugation  
As centrifugation is the method of choice to concentrate the microparticles, its 
influence on particle size distribution was analyzed. Moderate centrifugation is 
reversible, and the underlying bimodal distribution can be restored after 
vortexing (Figure 4-5).  
 
Figure 4-5: Particle size after centrifugation and resuspension 
4.1.1.4 Influence of Lyophilization  
The feasibility of lyophilization to create dry microparticles was tested. Dried 
particles might be desired to circumvent classic formulation instabilities of 
suspensions such as caking after sedimentation during storage [Defelippis et 
al., 2000]. Furthermore, protein stability might be further improved in the dry 
solid state, compared to protein particles in an aqueous environment. Finally, 
dry microparticles might serve as starting material for other formulation 
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approaches, e.g. incorporation in implants. Microparticles were first concen-
trated by moderate centrifugation, frozen in liquid nitrogen and then subjected to 
a lyophilization process. After subsequent dispersion, the larger population 
around 35 µm is favoured, although the smaller fraction is still present as a 
shoulder (Figure 4-6). For images of lyophilized microparticles see Figure 4-23. 
 
Figure 4-6: Particle size distribution of different batches after lyophilization  
The process is feasible to create dry microparticles. The underlying particle 
distribution can be preserved, emphasizing the importance of initial particle 
formation within the precipitation step. However, in some batches formation of 
associates larger than 100 µm is observed after lyophilization. This might be 
caused by the high protein concentration, forcing individual protein particles to 
close contact with each other during freezing and drying. Removal of water 
enables the particles to build up interparticular connections. As the result is 
given in volume%, the total number of these large aggregates is small.  
4.1.1.5 Influence of Protein Concentration and Batch Volume 
For the production of larger amounts of microparticles, a scaled-up procedure, 
combining microparticles of 12 batches with a total volume of 360 ml and an 
initial protein concentration of 2 mg/ml was performed and analyzed with 
respect to the particle size distribution (Figure 4-7). 
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Figure 4-7: Particle size distributions of a 30 ml batch after equilibration, centrifugation 
and pooling (2550G for 15 minutes, combination of 12 batches), and 
lyophilization  
The higher protein concentration and the larger batch volume did not alter the 
preferred particle sizes after equilibration. However, a tendency to form lager 
associates, with average sizes of approx. 250 µm becomes apparent, creating a 
third maximum. The particle fraction with a maximum at 5.8 ± 0.6 µm covers 
81.3 % of the total particle volume, the intermediate fraction 16.3 % and the 
large associates 2.4 %. Subsequent concentration by centrifugation and pooling 
to approx. 50 mg/ml increases the amount of medium sized associates on cost 
of the small ones. Lyophilization further pushes the balance towards this 
population, with mean sizes of 41.9 ± 4.2 µm at maximum. For the process 
steps precipitation and concentration by centrifugation, the particle size 
distributions from the scaled-up procedure differ only marginally from smaller 
scaled batches. After freeze drying and redispersion, the microparticle size 
slightly increases. Thus, higher initial protein concentrations and larger batch 
volumes are general feasible for scaling-up, keeping in mind that lyophilization 
alters the distribution.  
4.1.1.6 Variations of Mixing Technique and Protein Concentration  
The micromixer® enables laminar mixing of two liquids, the protein and the 
precipitation solution [Hessel et al., 2001] (Figure 4-8). The mixing process can 
be performed continuously, and the technique allows precise adjustment and 
variation of a number of parameters, e.g. the mixing speed by manipulation of 
the feed rate or by exchanging the inlays differing in the channel size. 
Furthermore, by parallel operation of multiple devices, this approach possesses 
unique scaling-up properties. To adapt the experimental design of the batch 
precipitation process to the setup and the dimensions of the device, identical 
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volumes of precipitation solution and protein solution are used (mixing ratio 
1 + 1).  
 
Figure 4-8: Experimental setup with micromixer®: two syringe pumps feed the 
micromixer® with a constant, pulsation-free flow of the protein and the 
precipitation solution, laminar mixing and precipitation is performed within 
the device, thus forming the microparticles. 
Again, precipitation is a time dependent process. After equilibration, similar 
particle distributions were found as in the precipitation experiments conducted 
with the vortex mixing technique. Both mixing techniques result in particle 
formation in the range of 0.5 to approx. 200 µm with a preferred size of approx. 
7 µm. Whereas precipitation via vortex results in a second peak with sizes 
around 30 µm, micromixing delivers larger particles in the 60 µm range after 
equilibration. The variation of the total inlet flow within 0.32 and 1.66 ml/min did 
not markedly affect the resulting particle size. Higher protein concentrations 
increase the volume fraction of the small microparticles, being well above 85 % 
(volume based) at a final precipitation concentration of 2.5 mg/ml (Figure 4-9).  
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Figure 4-9: Particle size distribution after laminar mixing and equilibration: bimodal, 
with preferred maxima at 7 and 60 µm 
The major disadvantage of the formulation is the difficulty to keep the pH 
constant. Repeated measurements over time indicate a shift by approx. 0.3 
units within 24 hours (Figure 4-10).  
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Figure 4-10: pH-shift of the formulation to more basic values over time: control and 
samples containing different amounts of precipitated microparticles. 
In contrast to physiologic blood fluid, which features diverse mechanisms to 
balance and maintain the pH, the artificial physiologic formulation lacks 
sufficient buffer capacity. With a concentration of 1 mM, the contribution of 
phosphate to the buffer capacity is minimal. With a maximal buffer capacity of 
bicarbonate being around pH 6.1, the contribution of 27 mM of this salt to the 
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buffer capacity is marginal at the target pH of 7.4, [Martin et al., 1987]. The 
observed pH increase might be the result of a CO2 loss to the environment 
Overall, controlled precipitation in the batch mode leads to the formation of 
protein microparticles suspended in an artificial physiologic environment. 
Scaling up is feasible by utilizing the continuous laminar mixing approach 
provided by the micromixer®. Dry microparticles can be obtained by 
concentrating (moderate centrifugation of the suspension) and subsequent 
lyophilization. 
4.1.2 Optimization of Formulation Composition 
To keep the pH constant, a sufficient buffer capacity should be introduced. 
Furthermore, the number of excipients present in the final microparticulate 
suspension should be reduced. At first, residual excipients derived from the 
protein bulk formulation, which was initially optimized for lyophilization (glutamic 
acid as buffer, sucrose and glycine as cryo/lyoprotectant and amorphous cake 
former) should be removed and replaced by an adequate buffer. Especially the 
surfactant (polysorbate) might interfere with the formation of particles and 
should therefore be eliminated. Secondly, the precipitation solution should be 
optimized by omitting bicarbonate and focusing on a single buffer system and 
adjusting to physiologic ionic strength with a single type of salt. This is 
legitimate, as the solubility of rhBMP-2 is mainly dependent on the ionic 
strength and not salt specific [Abbatiello et al., 1997].  
4.1.2.1 Solubility in Different Phosphate Buffer Systems 
An ideal candidate useful to optimize both the precipitation and the protein 
solution is phosphate buffer. It can serve as protein formulation buffer to support 
solubility in the acid milieu (pK1 = 2.16) and as precipitate stabilizing buffer after 
shift to physiological pH (pK2 = 7.21) and salt content. Therefore, the solubility 
of different phosphate buffer systems was tested. Figure 4-11A shows the 
residual protein solubility in dependence of the ionic strength at different pH 
values and phosphate buffer molarities. Salting-in of rhBMP-2 is observed over 
the entire observed ionic strength, ranging from 22 – 280 mM. Thus, an in-
crease in buffer molarity is accompanied by an increase in solubility of the 
protein. The differences in solubility of equimolar buffers of different pH values 
are also a direct consequence of the altered ionic strength, with formulations of 
higher pH values featuring higher ionic strengths. The solubility profile is in good 
correlation with the literature (see Introduction). Extrapolation at the target ionic 
strength of 154 mM delivers protein solubility in the range of 0.03 to 0.04 mg/ml.  
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Figure 4-11: Residual solubility of rhBMP-2 in dependence of the ionic strength and pH 
(a), at constant final ionic strength of 154 mM (adjusted with KCl) and 
different buffer molarity and pH (b)  
Figure 4-11B shows the residual solubility of rhBMP-2 in phosphate buffer 
formulations with different pH values and buffer molarities, adapted with KCL to 
a final ionic strength of 154 mM to mimic physiological conditions. Within the 
accuracy of the measurement, similar solubility’s are obtained at different pH 
values, but equimolar ionic strengths, confirming the finding that solubility of 
rhBMP-2 is mainly dependent on the ionic strength. The 50 mM buffer with a pH 
of 7.4 is selected for the novel formulation, as it features the highest buffer 
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capacity and requires the fewest amount of KCl to adapt the ionic strength to 
154 mM. These conditions are optimal because the administration of a protein 
suspension with a higher ionic strength is expected to result in uncontrolled 
precipitation of residual soluble protein at the injection site, whereas in solutions 
with lower ionic strength microparticles are thought to be subjected to rapid 
redissolution. 
4.1.2.2 Particle Size Distribution of Optimized Formulation 
Microparticles were prepared according to the optimized formulation 
composition: the protein formulation was buffer exchanged into 50 mM 
phosphate, and the composition of the precipitation solution was reduced to the 
excipients KCl and KOH to increase the pH and the ionic strength to induce 
precipitation. In order to be able to use laser light diffraction measurements 
(Malvern® Mastersizer) for the analytics without the need to dilute the sample, 
initially low final protein concentrations were used. Turbulent mixing of the 
protein solution (c = 0.2 mg/ml) with the precipitation solution in a 9 + 1 ratio 
results in a final protein concentration of approx. 0.18 mg/ml.  
 
  
Figure 4-12: Time dependent particle formation and equilibration distribution of 
optimized formulation: maxima at 7.1 ± 0.7 µm, 34.4 ± 3.4 µm and 
203.5 ± 20.0.  
Figure 4-12 depicts the course of particle growth on cost of an initially formed, 
almost monomodal particle population. At equilibrium, the same two maxima 
are obtained as in the previous, more complex formulation (Figure 4-3). 
However, a slight tendency to form associates of approx. 200 µm can be 
observed.  
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With a residual solubility of approx. 0.03 mg/ml (Figure 4-11), higher final 
precipitation concentrations than the initially tested 0.18 mg/ml are desired to 
increase the ratio of immobilized to soluble protein and thus the precipitation 
efficacy. However, at higher protein concentrations the phosphate buffered 
protein solution shows premature precipitation already before the precipitation 
solution is added. Consequently, the protein solution is reformulated without 
phosphate at an acidic pH of 3.0 to ensure solubility (1 mM HCl), and the 
phosphate buffer component is added with the precipitation buffer.  
Figure 4-13 compares the equilibrium distributions of the formulation with 
phosphate in the protein solution (mixing ratio of 9 + 1, final protein 
concentration 0.18 mg/ml), and the modified formulation with the phosphate salt 
in the precipitation solution (mixing ratio of 1 + 1, final protein concentration 
0.18 mg/ml and 1.0 mg/ml. Apart from a slightly broader peak for the small 
particle fraction and a shoulder instead of a discrete maximum for the particle 
fraction around 30 µm of the low concentrated formulation, essentially the same 
distribution patterns are obtained independent of the mixing ratio.  
 
Figure 4-13: Equilibrium distributions of optimized formulations after turbulent mixing 
basically show the same distribution pattern: prominent maxima at 
7.1 ± 0.7 µm and 34.4 ± 3.4 µm.  
To elucidate scaling-up properties of the optimized formulation, microparticles 
were generated by laminar mixing of equal volume flows of precipitation solution 
and protein solution, resulting in a high final protein concentration of 1 mg/ml. 
Figure 4-14 shows the course of particle formation. In analogy to previous 
results, an almost monomodal population with maximum around 7 µm can 
initially be detected, which gives way to a bimodal distribution after equilibration 
for one hour.  
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Figure 4-14: Time dependent particle formation of optimized formulation after laminar 
mixing: maxima at 7.1 ± 0.7 µm and 41.9 ± 4.1µm 
Further proof of the robustness and the high scaling-up potential of the method 
can be concluded from Figure 4-15. It shows essentially the same distributions 
of three batches prepared with different feeding rates and confirms the 
independence of particle size from this parameter.  
 
Figure 4-15: Particle distribution after laminar mixing with different flow rates and a high 
final protein concentration of 1.0 mg/ml after equilibration for one hour.  
4.1.2.3 Phase Contrast Microscopic Imaging of Microparticles 
The presence of large aggregates as they were detected by laser light 
diffraction measurements (Figure 4-12) cannot be confirmed by visual 
inspection. In the non-stirred diffraction measuring cell, the highly hydrated 
microparticles interact with each other, forming a network-like structure. 
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Consequently, two originally individual particles might appear to be a single, 
large one for the measuring system. With phase contrast microscopy, it is 
possible to visualize the microparticles. Figure 4-16 clearly demonstrates that 
the microparticles measure far less than 100 µm. Individual irregular shaped 
particles sizing approx. 1 to 30 µm can be seen, and larger microparticles 
appear to be loose agglomerates of smaller ones. Contrary to laser light 
diffraction measurements, the average size of initially formed particles remains 
essentially the same over time. Consequently, the large particle population 
measured with laser light diffraction is an artifact, caused by weakly associated 
small particles. In analogy to laser light diffraction results, the microscopic 
images also do not reveal a fundamental difference between samples prepared 
by turbulent and laminar mixing.  
 
 
Figure 4-16: Images of microparticles with phase contrast microscopy prepared by 
different mixing techniques: turbulent mixing and equilibration for 10 min 
(a), 1 h (b), 64 h (c); laminar mixing and equilibration for 10 min (d), 1 h 
(e), 24 h (f) 
The microscopic images show collectives of particles which seem to be 
individual ones. Minimal liquid streams caused by covering the suspension drop 
with the slit during sample preparation initiate the particles to move and come to 
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rest side by side, so that they appear to form large particles in the microscopic 
image (Figure 4-17a,b). Marginal shear forces, caused by a slight push of the 
cover slit, singles the particles out (Figure 4-17c,d). This observation further 
supports the assumption that larger microparticles are loose associates of 
compact, small ones.  
 
 
Figure 4-17: Particle size distributions before (a, b) and after manipulation of the cover-
slit (c, d) 
4.1.2.4 Laser Light Blockade Measurements 
To support the hypothesis that large particles consist of loosely associated 
small particles, laser light blockade experiments were performed. This setup 
allows the measurement of the suspension on the move, as the sample is 
pumped to the optical system, thus separating loose associates due to shear 
forces. The data confirm that the optimized formulations do not contain any 
particle larger than 48.7 µm, and the percentage number of particles larger than 
8.3 µm is below 1 %. Over 30 % of the particles fall in the size category of 
1.4 µm (Figure 4-18). Comparison of the data acquired with LLD with the results 
of laser blockade measurements must be done with care, as the first technique 
delivers volume distributions, whereas the latter is based on particle numbers.  
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Figure 4-18: Particle number distributions of optimized formulation, measured with 
laser light blockage (PAMAS®)  
4.1.2.5 Effect of Polymers and Surfactants  
The variation of process parameters and the modification of the formulation did 
not allow the adjustment of a predetermined uniform particle size. The 
optimized formulation delivers small particles in the range of 1-2 µm, which tend 
to form larger collectives of loosely associated small particles. Two approaches 
are followed to gain tighter control over the particle size: (i) stabilization of these 
individual small particles and prevention of additional particle growth and (ii) 
formation of a homogeneous population of large and robust particles. In a small 
set of experiments, the effect of some selected additives on the particle size 
distribution was tested and evaluated by microscopic imaging (Figure 4-19). As 
BMP carries a positive net charge below its pI of 8.2, coprecipitation with 
poyanionic excipients is a promising approach to achieve larger particles 
[Dumitriu et al., 1998]. The polyanionic mucopolysaccharide hyaluronic acid is a 
mayor component of connective tissues such as the synovial fluid of joints, the 
scaffold within the cartilage and the vitreous fluid of the eye [Segura et al., 
2005]. It is involved in a number of physiologic processes, such as cell 
hydration and differentiation, poteoglycan organization and wound healing (Kim 
2001), and its safety is demonstrated by a number of commercially available 
products (e.g. Hyalart® for injection, DuoVisc® eye drops, HYA Ophtal® solution 
for intraocular use; http://www.rote-liste.de). Furthermore, derivates based on 
hyaluronic acid were evaluated for their use as biomaterials due to their well 
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established biocompatibility [Hyun, 2004]. Another biopolymer with polyanionic 
properties at physiologic pH is sodium alginate. It is a well known agent in the 
food industry, and alginate matrixes are widely used for encapsulation of 
proteins [Gombotz et al., 1998]. Coppi et al. demonstrated complex formation 
between alginate and BSA at pH values below the isoelectiec point of the 
protein [Coppi et al., 2002]. Finally, acidic gelatin (type B) was tested as 
polyanionic counterpart to build insoluble complexes with the basic rhBMP-2. 
The safety of gelatin, a decomposition product of collagen, is proved by its long 
clinical usage as plasma expander, in surgical materials and as ingredient in 
drugs [Tabata et al., 1998]. The natural occurrence of hyaluronic acid and 
gelatin in cartilage and bone related tissues make them particularly suitable for 
formulations targeting these areas. For the same reason, chondroitinsulfate was 
included. None of the polymeric excipients resulted in a tighter control over the 
microparticle size (Figure 4-19). The formulations containing chondroitinsulfate 
and gelatin seem to favor larger aggregates, but again a uniform distribution 
cannot be achieved. 
 
Figure 4-19: Phase contrast microscopic images of microparticles prepared with 
different concentrations of polyanionic biopolymeric additives: control (a), 
0.1 % sodium alginate (b), 0.25 % hyaluronic acid (c), 1 % chondroitin-
sulfate (d), 0.1 % gelatin (type B 175 bloom) (e) 
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The use of the two surfactants polysorbate 80 (polyoxyethylenesorbitan 
monooleat, Tween® 80) and poloxamer (Lutrol®F68) is based on the 
observation that larger associates are formed from an initial monomodal 
microparticle population (see 4.1.1.2). The surfactants might cover the 
hydrophobic surfaces of the primary particles, leading to minimization of 
attractive forces between individual microparticles, thus keeping them 
separated. Compared to the control and the polysorbate 80 formulation, the 
poloxamer tends to prevent association among microparticles. However, the 
overall distribution is not uniform, and larger associates are still present (Figure 
4-20).  
 
Figure 4-20: Influence of surfactants on particle separation: 1 % poloxamer (a), 1 % 
polyoxyethylenesorbitan monooleat (b) 
To summarize, the addition of the tested excipients has only minor influence on 
the appearance of the microparticles and do not allow a tighter control of the 
particle distribution.  
4.1.2.6 Gel Formulations 
The observation that the large particle fraction consists of loosely associated 
smaller ones led to the idea to separate them by slight shear forces and to 
prevent reassembling of single microparticles by increasing the viscosity of the 
dispersant. As Povidon K17, a low molecular weight polyvinyl pyrrolidone with 
approval for injectable products, only marginally increases the viscosity even at 
high concentrations of 40 % (w/v), its high molecular derivate Kollidon® 90 was 
chosen as a model thickening agent. Figure 4-21 shows microscopic images of 
formulations containing different amounts of Kollidon® 90. Up to 10 % (w/v) 
gelling agent, the images of the formulations still show distinct agglomerates. 
12.5 % are sufficient to keep the microparticles separated. The highest tested 
concentration of 15 % did not show further improvement (Figure 4-21). Viscosity 
measurements suggest Newton-like behavior, with 24 mPa s for 5 %, 129 
mPa s for 10 %, 244 mPa s for 12.5 % and 443 mPa s for the 15 % gels.  
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Figure 4-21: rhBMP-2 microparticles suspended in formulations with different 
concentrations of Kollidon® 90: 5 % (a), 10 % (b), 12.5 % (c), 15 % (d) 
Due to the increased viscosity, laser light diffraction measurements were 
difficult to perform, as air bubbles were introduced during sample preparation 
which would be falsely considered to be particles. For the same reason, laser 
light blockade measurements are not suitable. By visual inspection, the formed 
microparticle suspension appears to be homogeneous. It could be shown that 
the approach of marginal shear forces caused by simple mixing in combination 
with increase of viscosity is suitable to separate and stabilize the primary 
particles. Furthermore, the release of rhBMP-2 from microparticles incorporated 
in a gel might be further prolonged, which would be advantageous. The high 
molecular weight polymer Kollidon®90 only serves as a model thickening agent. 
For a commercial product other biodegradable and approved biopolymers e.g. 
cellulose derivates might be preferable. With a viscosity of 224 mPa s for the 
12.5 % gel, syringeability should still be given.  
4.1.3 Scanning Electronic Microscopy 
Imaging of suspended rhBMP-2 microparticles has proven to be afflicted with a 
number of difficulties. Standard microscopy fails probably due to the marginal 
differences in the diffraction index between the highly hydrated protein particles 
and the dispersant water. For the same reason, techniques based on laser light 
reflection are considered to be unsuitable. With phase contrast microscopy, the 
hurdle of low diffraction index differences can be overcome. However, this 
technique is critical as shear forces during the sample preparation disturb the 
original particle size and geometry (Figure 4-17). AFM is not suitable, since the 
high resolution is thought to deliver macroscopic details of the particle surface 
rather than an overview of the whole microparticle. Consequently, the 
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microparticles were investigated with Environmental SEM, a modified SEM 
technique which allows the imaging of samples under adjustable conditions of 
relative humidity without previous blending of the sample with gold. As this 
technique can only visualize solid surfaces which are not submersed in water, a 
highly concentrated microparticle suspension was prepared and by the 
reduction of the pressure at constant temperature the water was removed, 
uncovering the microparticles. The removal of the liquid causes the 
microparticles to build up a dense layer of particles sticking together (Figure 
4-22a). Furthermore, a spontaneous formation of spheres can be observed. 
Apart from this artifact formation, an initial particle size of approx. 1-5 µm, with 
an almost spherical particle size might be guessed from the images (Figure 
4-22a,b).  
  
Figure 4-22: ESEM images of formulation at 800 (a) and 3000 (b) magnification 
Overall, ESEM is not suitable to visualize the microparticles in the aqueous 
environment. However, the spontaneous formation of spherical particles, which 
is observed as a consequence of the water removal, might also occur during 
lyophilization of highly concentrated suspensions, thus explaining the shift in 
particle size. Furthermore, it underlines the tendency of the microparticles to 
stick together and form larger aggregates.  
100 µm 20 µm 
a b
66 Results and Discussions 
  
  
Figure 4-23: SEM images of precipitated microparticles after lyophilization at increasing 
magnification (a-d) 
Images of freeze dried microparticles visualized with classic SEM are given in 
Figure 4-23. They show a rather heterogeneous particle distribution, with sizes 
partially exceeding 100 µm. Although care was taken to preserve the 
distribution present in the aqueous protein suspension (shock-freezing by 
submersing into liquid nitrogen) the large particles are supposed to be the 
consequence of the drying process (Figure 4-23a), as already indicated in the 
ESEM images. Beside these artifacts, particles of approx. 10 µm and 30-40 µm 
are visible, which is in good correlation to the results of laser light diffraction 
measurements (Figure 4-23b). Higher magnification uncovers a rough surface 
of the associates (Figure 4-23c). The crystalline structures seen at the highest 
magnification in Figure 4-23d are supposed to be inorganic salt, whereas the 
amorphous structures dominating the large particles were build up by small 
individual primary protein particles with sizes of approx. 1 µm. 
4.1.4 Mechanistic Studies on Particle Formation with PCS 
To gain insight further into the initial particle formation process during 
precipitation and the underlying mechanism, PCS measurements were 
performed. Standard formulations could not be directly measured as the 
suspensions were too concentrated to be measured without further dilution and 
the sizes of the formed microparticles exceed the measuring range. During the 
100 µm 10 µm 
40 µm 4 µm 
dc 
ba 
Results and Discussion - Formulation Development 67 
precipitation process of rhBMP-2, both the pH and the ionic strength are shifted. 
Consequently, particle formation can be induced (i) by the pH shift, which would 
suggest an isoelectric precipitation mechanism, (ii) by the increase of the ionic 
strength, correlated to a salt induced precipitation mechanism, or (iii) by a 
combination of both. To differentiate between these mechanisms, experiments 
were performed analyzing both the precipitation behavior caused by solely 
shifting the pH under otherwise constant ionic strength and by an increase of 
the ionic strength at constant pH.  
The ionic strength of a acidic protein solution (pH = 3.0) was increased by 
stepwise addition of KCl and monitored with PCS for aggregates. At a high 
protein concentration of 5.0 mg/ml, up to an ionic strength of approx. 25 mM, an 
effective diameter of 5.8 nm can be obtained. At 91 mM, an increase of the 
effective diameter to 11 nm indicates the beginning of molecule association. A 
further increase in ionic strength to 200 mM led to the formation of insoluble 
particles with sizes exceeding the resolution power of PCS (Table 4-2). After 
reduction of the protein concentration to 2.0 mg/ml (the starting concentration of 
the protein stock solution for precipitation experiments) no hints for precipitation 
can be detected with PCS over the tested ionic strength range, even at values 
exceeding the target of 154 mM (data not shown). Consequently, no precipi-
tation would be expected at even lower concentrations, e.g. the usually 
employed precipitation concentration of 1 mg/ml and pH 3.0.  
Table 4-2: Influence of ionic strength on particle formation at pH 3.0 and high protein 
concentration of 5.0 mg/ml 
# 
 
pH 
 
ionic strength 
[mM] 
effective diameter 
[nm] 
polydispersity
 
1 3.0 24.3 5.8 0.187 
2 3.0 91 11.0 0.237 
3 3.0 200 3071.8 0.273 
 
In general, a final protein concentration of 1 mg/ml was targeted for 
microparticle generation. Consequently, the influence of pH was analyzed at 
this concentration. The influence of the ionic strength was tested by measuring 
both low (without KCl) and at high levels (adjusted with KCl). The pH was 
increased by stepwise addition of a 0.1 M NaOH solution.  
In the samples without KCl supplementation, pH ranges of 3.0 to 5.4 did not 
lead to detectable protein association. A very narrow monomodal distribution 
with an average size of 8.6 nm can be found. At pH 6.5, particle association 
occurs, leading to a substantial increase of the polydispersity index and a 
moderate increase of the effective diameter. Higher pH values lead to sizes 
exceeding the upper limit of the resolution of PCS (Table 4-3).  
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Table 4-3: pH-shift at low Ionic strength and a protein concentration of 1.0 mg/ml 
rhBMP-2 
# 
 
pH 
 
ionic strength 
[mM] 
effective diameter 
[nm] 
polydispersity 
 
1 5.33 0 8.6 0.094 
2 6.49 0 11.6 0.245 
3 8.54 0 1521.6 0.265 
 
In the precipitation experiments supplemented with potassium chloride (I=130 
mM) stable protein size data up to a pH of 4.2, and comparable parameters for 
the polydispersity index and the effective diameter to the approach without KCl 
were obtained. An additional minimal pH increase of approx. 0.4 units extremely 
pushes both the effective diameter and the polydispersity index to higher 
values. After a continued addition of NaOH to a pH value of 4.7, the particles 
formed exceed the valid detection range (Table 4-4).  
Table 4-4: pH-shift at high ionic strength and a protein concentration of 1.0 mg/ml 
rhBMP-2 in HCl (pH=3) 
# 
 
pH 
 
ionic strength 
[mM] 
effective diameter 
[nm] 
polydispersity 
 
1 4.18 130 8.3 0.068 
2 4.56 130 1293.7 0.207 
3 4.72 130 2335.3 0.273 
 
PCS measurements are suitable to determine the onset of particle formation, 
although it is was not possible to detect distinct intermediates reflecting a 
preferred aggregation pattern. At acidic pH values, protein concentrations below 
2 mg/ml are not sufficient to cause precipitation by solely increasing the ionic 
strength up to a value of 334 mM. As compared to usually employed salting-out 
concentrations of several moles [Simpson, 2004b], the herein utilized amounts 
of KCl are quite low, suggesting an ion specific binding mechanism to be more 
likely than a classic salting-out process. This observation supports the finding of 
Abbatiello, who suggests an anion mediated bridging of rhBMP-2 molecules 
[Abbatiello et al., 1997]. Shifting the pH towards the isolelectric point already 
induces precipitation. Compared to samples without salt supplementation, the 
effect of the pH shift is more evident at an ionic strength of 130 mM, and particle 
formation is induced almost 2 units earlier. The results are in good agreement to 
the unusual solubility profile of rhBMP-2. In conclusion, both the pH and the salt 
contribute to the generation of microparticles by precipitation.  
Results and Discussion - Protein Integrity 69 
4.1.5 Summary 
RhBMP-2 microparticles can be generated by controlled precipitation mimicking 
artificial physiological conditions. Particle formation is a time dependent 
process, and bimodal distributions are obtained after equilibration, with 
preferred sizes of 7 and 35 µm at maximum. Batch precipitation using turbulent 
mixing features good scaling-up properties. Both an increase of protein 
concentration and the batch volume have only minor effects on the particle 
distribution at equilibrium. Another helpful tool for scaling up is the micromixer®, 
which allows laminar and continuous mixing of the precipitation solution with the 
protein solution. Similar bimodal distributions were obtained with this device 
compared to the turbulent batch approach, delivering particles in the range of 
0.5 to 200 µm.  
The recovery of microparticles after lyophilization of the microparticle 
suspension is generally possible. At final protein concentrations of 1 mg/ml, the 
underlying particle distribution can be preserved after resuspension. Freeze 
drying of highly concentrated suspensions shifts the particle size from approx. 
35 µm to over 40 µm.  
Optimization of the formulation leads to a reduction in the excipient number 
without an alteration of the particle distribution. Finally, the aqueous protein 
suspension is composed of rhBMP-2, phosphate buffer and potassium chloride. 
Three strategies were followed to gain a tighter control of the particle size, 
potentially leading to a monomodal distribution: (i) prevention of ongoing 
association of initially formed small particles by surfactants (ii) formation of 
larger particles by coprecipitation with polyionic macromolecules (III) separation 
of primary particles and prevention of particle growth by increasing the viscosity 
of the dispersant. Whereas the first two approaches did not lead to the desired 
result, the increase of the viscosity of the dispersant with a model thickener 
PVP has proven to be a potent tool to prevent the formation of larger 
associates, leading to a homogeneous particle suspension. 
4.2 Protein Integrity 
4.2.1 Process Stability of Precipitation  
A major concern of a formulation based on precipitation is that the process may 
harm the protein. Alterations in the protein’s secondary and tertiary structure, 
also referred to as denaturation, might be induced, which subsequently leads to 
instabilities such as adsorption to surfaces, aggregation or unwanted 
precipitation [Manning et al., 1989]. This might result in reduced bioactivity or 
increased immunogenicity [Wang, 1999]. Thus, even minimal amounts of 
aggregates can render a parenteral formulation unsuitable. Therefore, it should 
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be demonstrated weather precipitated microparticles can easily be redissolved, 
delivering the native, soluble and bioactive protein. 
4.2.1.1 Aggregation 
To show that the redissolved microparticle formulation does not show increased 
aggregate formation, microparticles were prepared by precipitation, equilibrated 
at 25°C and resolubilized after predetermined time intervals by adding the 
formulation buffer used for the lyophilized formulation. The aggregate content of 
the resolubilized samples was quantified by SEC and compared with the results 
of native, untreated rhBMP-2 reference material. 
Redissolution resulted in clear solutions, with no turbidity indicating aggregates 
visible. SEC analysis did not reveal a significant increase in the high molecular 
weight species content as compared to unstressed rhBMP-2, even if the 
precipitate was allowed to age for 25 hours (Figure 4-24). Consequently, the 
coherence within the precipitated microparticles can be completely broken and 
the precipitation process did not induce the formation of aggregate-competent 
intermediates. 
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Figure 4-24: Soluble aggregates present before precipitation in the native soluble 
formulation (control) and after precipitation at 0.5 mg/ml rhBMP-2 (?) and 
1.0 mg/ml rhBMP-2 (?) and subsequent resolubilization at denoted times 
in formulation buffer 
4.2.1.2 Conformational Stability 
FTIR provides a powerful tool to analyze the conformation of proteins. The 
amide I band is most commonly used to study protein structures since its band 
shape is very sensitive to the protein secondary structure. It is dominated by the 
signals of the carbonyl stretching vibration of the polypeptide backbone, 
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appearing in the spectral region between 1610 and 1700 cm-1 [Barth et al., 
2002]. 
 
Figure 4-25: Idealized FTIR spectra of the amide I region of model proteins depicting 
(a) random coil structures, (b) α-helical structures, (c) β-sheet structures 
The model spectra seen in Figure 4-25 depicture band shapes of proteins solely 
featuring a single structure. In reality, proteins are more complex, and 
overlapping signals lead to a more or les broad and featureless amide I 
spectrum. This makes it difficult to identify discrete bands and to assign them to 
the adequate substructure. Therefore, resolution enhancement techniques are 
required. The advantage of second derivative calculation as compared to 
Fourier self-deconvolution as possible band-narrowing technique lies in the fact 
that there is no need to choose subjective parameters, and therefore is 
completely objective [Fabian et al., 2000]. Every band or shoulder in the original 
spectrum results in a negative band in the second derivative. 
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4.2.1.2.1 Analysis of Conformational Integrity 
CD spectroscopy cannot be used to investigate the secondary structure of 
precipitated particles due to interfering light scattering [Kendrick et al., 1998]. In 
Raman spectroscopy, high fluorescence disturbs the measurement. The great 
advantage of FTIR lies in the fact that the physical state of the sample is less 
relevant, thus allowing insight into the secondary structure even in the 
precipitated state. To elucidate the influence of precipitation on the secondary 
structure of rhBMP-2, FTIR spectra before precipitation, in the precipitated state 
and after resolubilization were recorded and compared. Figure 4-26 shows 
normalized second derivative spectra of rhBMP-2 formulations featuring 
different sample histories: native rhBMP-2 (1 mM HCl), precipitated rhBMP-2 
microparticles (physiological environment) and resolubilized microparticles 
(formulation buffer). The obtained spectra depict great overall similarity. All 
show the strong band at 1631 cm-1, which can be assigned to β-sheet structure, 
and the weaker one at 1680 cm-1, which is associated in the literature with 
β-turns. Furthermore, a band around 1658 cm-1 which is attributed to α-helical 
structure elements, and a band at 1646 cm-1 which reveals unordered 
structures can be identified [Barth et al., 2002, Dong et al., 1990, Susi et al., 
1988]. As only minor differences in the intensities of some peaks are apparent, 
it can be concluded that no structural changes are induced by the precipitation 
process. The native secondary structure is maintained in the precipitated 
rhBMP-2 microparticles. Furthermore, precipitation is fully reversible, and the 
native structure is preserved after resolubilization. In the literature, additional 
proof for the integrity of proteins in the precipitated state can be found by 
Stratton and coworkers. They demonstrate for lactate dehydrogenase and 
α-chymotrypsin precipitated in a poloxamer gel that the native structure is 
maintained [Stratton et al., 1997]. Native-like secondary structure, measured by 
FTIR, was also found by Kendrick et al. for rhIFN-γ precipitated with PEG 8000. 
The authors outlined the difference between a destructive aggregation mainly 
caused by destabilizers directly influencing the conformation of the protein and 
salt induced precipitation based on the reduced solubility of the macromolecule 
due to the altered solvent [Kendrick et al., 1998]. The maintenance of the 
secondary structure in the precipitated state demarcates this kind of 
precipitation from non-native protein aggregation, where partly unfolded protein 
molecules (molten globules) are thought to be the reactive species responsible 
for protein assembly [Chi et al., 2003].  
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Figure 4-26: Area normalized, second derivative spectra of dialyzed (········), 
precipitated (−−−−) and resolubilized (——–) rhBMP-2 
4.2.1.2.2 Determination of Structural Composition via FTIR  
Secondary structure element determination of native, liquid rhBMP-2 resulted in 
9.5 % α-helix and 25 % ß-sheet. Whereas the value for the α-helix is in good 
correlation to data from X-ray crystallography (9.5 vs. 8 % α-helix), the 
calculation for the ß-sheet content varies considerably (25 % vs. 42 % ß-sheet 
structure) [Scheufler et al., 1999]. This might be due to structural differences 
between the solved and the crystallized form of rhBMP-2 and the fundamental 
physicochemical differences between the techniques used.  
4.2.1.2.3 Temperature Ramp of Precipitated and Redissolved Protein  
Temperature ramps of both precipitated and resolubilized samples were 
performed and compared to address the question if possible variations in the 
secondary structure can be uncovered at higher temperatures. Figure 4-27 
shows temperature induced changes in the secondary structure of precipitated 
microparticles. Up to 70°C, only continuous deviations in the intensities of the 
main bands compared to the previous temperature step appear, but significant 
changes in the curve patterns are absent. At 73°C, peak shifts that give 
evidence to a significant change in secondary structure become obvious. It is 
accompanied by clear losses of α-helical (1658 cm-1) and β-turn structures 
(1680 cm-1). Furthermore, a novel band at 1690 cm-1, which can be assigned to 
intermolecular β-sheet structures, is formed [Dong et al., 1995]. At higher 
temperatures the band intensity at 1690 cm-1 further increases and above 91°C 
the formation of an additional band at approx. 1622 cm-1 is induced. 
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Figure 4-27: Second derivative, area normalized amide I spectra of temperature 
induced re/unfolding of precipitated rhBMP-2 microparticles; the arrows in-
dicate the direction of intensity shift at wavenumbers of interest with rising 
temperatures from 25°C - 70°C (········), 73°C (——–), 76°C - 94°C (−−−−). 
Figure 4-28 illustrates temperature dependent re- and unfolding of resolubilized 
rhBMP-2 microparticles. In contrast to the precipitated material, the band 
contour between 1640 and 1680 cm-1, which includes α-helical structures at 
1658 cm-1, is mainly preserved as the temperature is increased. However, the 
resolubilized sample also shows the formation of additional bands at 1690 and 
1627 cm-1. 
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Figure 4-28: Second derivative, area normalized amide I spectra of temperature 
dependent re/unfolding of resolubilized rhBMP-2; the arrows indicate the 
direction of the intensity shift at wavenumbers of interest with rising 
temperatures from 25°C - 70°C (········), 73°C (——–), 76°C - 94°C (−−−−). 
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The gradual intensity shift at 1642 cm-1 seen in both the precipitated (Figure 
4-27) and the resolubilized (Figure 4-28) sample indicates a loss of β-sheet 
structures which are not completely resolved by band narrowing from the 
underlying unordered structures at 1645 cm-1. Both samples show the formation 
of additional peaks at 1690 cm-1 and 1622 cm-1 (for the precipitated sample) 
and 1627 cm-1 (for the resolubilized sample) respectively. According to the 
literature, it is a common feature of thermally unfolded proteins to exhibit a low-
frequency indicator band around 1620 cm-1 and a weaker high-frequency band 
around 1685 cm-1, assigned to intermolecular antiparallel β-sheet structures. As 
these wavenumbers were determined in D2O, slightly higher values will result in 
H2O [Fabian et al., 2000]. Therefore, the change in band structure fits into the 
scheme of thermal unfolding. Interestingly, the observed structural losses were 
not accompanied with an increase in the peak at 1645 cm-1 representing 
unordered structures. The degree of loss of β-sheet structure (1630 cm-1) in 
favour of antiparallel intermolecular β-sheet formation is more pronounced in 
the precipitated microparticles, and the α-helical structures are partially 
conserved in the resolubilized sample. The gradual overall shift of the intensities 
is explained by the conformational mobility of proteins and the assumption that 
not all protein molecules react to the altered conditions at the same time. 
Consequently, a loss of intensity at certain wavenumbers is caused by a 
structural loss of a certain population of protein molecules, whereas other 
molecules still exhibit the native conformation. With increasing temperatures, 
the balance between native and denatured protein molecules is further pushed 
into the direction of the denatured fraction.  
To abstract, the alterations in the curve progressions of the amide I spectra are 
quite similar for both the precipitated and the resolubilized sample up to a 
temperature of 73°C and 76°C respectively. Up to these temperatures, no 
change in the secondary structure that could be attributed to the former 
precipitation process is detectable. At higher temperatures, heat-induced 
denaturation takes place. At these temperatures, the contribution of other 
parameters (e.g. the physical state of the samples: direct contact between 
protein molecules in the solid microparticles compared to soluble rhBMP-2 
molecules) to the observed unfolding cannot be distinguished from the effect 
caused by potential structural changes. Even under the assumption that 
undetectable structural changes are induced during precipitation, the higher 
thermal resistance of the resolubilized sample at temperatures above 70°C as 
compared to the precipitated sample supports the hypothesis that these 
changes were completely offset after resolubilization. 
4.2.1.2.4 Unfolding Temperatures Determined with ATR-FTIR 
In the following, the transition temperature should be determined from the 
unfolding spectra. Chechin and co-workers use the intensity ratio decreasing to 
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increasing band (1618 cm-1 to 1650 cm-1) to determine the transition tem-
perature Tm (spectroscopy) from infrared spectroscopic measurements [Chechin et 
al., 1998]. In our studies, all bands with decreasing intensities show slight shifts 
in their maxima at higher temperatures, suggesting that they are not only due to 
structural losses. To estimate Tm from the temperature induced unfolding 
spectra, the intensity of the new arising band at 1690 cm-1 is plotted against 
temperature (Figure 4-29). Sigmoid curve fitting and differentiation deliver the 
point of inflection. The corresponding temperature at the inflection point is 
considered to be the transition temperature Tm (spec.). For the precipitated 
sample, Tm (spec.) was determined to be 75°C as compared to a slightly higher, 
but not significantly different transition temperature of 77.6°C for the 
resolubilized sample.  
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Figure 4-29: Transition temperatures of (?) precipitated and (?) resolubilized rhBMP-2 
based on the intensity shift at 1690 cm-1 (sigmoid fit: R2 = 0.990 (——–), 
R2 = 0.988 (········)) 
To confirm the findings obtained with the spectroscopic approach, DSC 
measurements were performed to determine Tm (cal.) calorimetrically. It is well 
known from the literature that several factors such as formulation composition, 
pH, concentration and measuring conditions can affect Tm (cal.) of a given 
protein. At first, the influence of formulation, pH, and composition were investi-
gated. It was demonstrated that samples containing between 1 and 5 mg/ml 
native rhBMP-2 in formulation buffer, Tm (cal.) is 64.3°C without statistically 
significant differences. Subsequently, all measurements were performed at 
2 mg/ml to avoid any possible influence on Tm (cal.) due to concentration effects. 
As the controlled precipitation of rhBMP-2 to form microparticles is partly 
caused by an increase of pH to physiological values, the influence of pH on the 
transition temperature of rhBMP-2 is of special interest. With an increase of the 
pH from 3.0 to 5.5, the transition temperature rises from 48.1°C to 70.2°C 
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(Figure 4-30). In parallel to the Tm shift, the calorimetric enthalpy increases 
(Table 4-5).  
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Figure 4-30: Thermograms of rhBMP-2 in formulation buffer at different pH values: 3.0 
(−−−−), 4.5 (········), 5.5 (——–).  
The observed Tm shift can be explained based on repulsive forces present in 
the molecule. RhBMP-2 is a basic protein with an isoelectric point of 8.5. At low 
pH values, the carboxylic acid side chains are preferentially uncharged, 
whereas the dominating fraction of basic groups carries positive charges. This 
is energetically unfavorable due to repulsive forces. With increasing pH values, 
the net positive charge diminishes and so do the repulsive forces, leading to an 
increase in Tm.  
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Table 4-5: Transition temperatures and calorimetric enthalpies of different rhBMP-2 
formulations 
sample description 
 
pH 
 
Tm (calorimetry) 
[°C] 
calorimetric enthalpy 
[kcal/mol] 
soluble rhBMP-2 in 1 mM 
HCl 3.0 54.8 ± 0.05 107.2 ± 7.0 
resolubilized microparticles 
in1 mM HCl 3.0 54.6 103.4 ± 0.7 
soluble rhBMP-2 in 
formulation buffer 4.5 64.3 107.0 ± 1.6 
resolubilized microparticles 
in formulation buffer 4.5 63.9 ± 0.05 86.7 ± 1.3 
precipitated microparticles in 
physiologic phosphate buffer 7.4 70.0 ± 0.05 165.1 ± 4.4 
soluble rhBMP-2 in 
formulation buffer 3.0 48.5 ± 0.05 52.5 ± 1.9 
soluble rhBMP-2 in 
formulation buffer 5.5 70.2 126.0 ± 4.5 
 
The excipients also affect the transition temperature. For example, two different 
formulations of the same pH vary significantly in their unfolding behavior. 
Whereas rhBMP-2 in 1 mM HCl shows a Tm of 54.8°C, the Tm is more than 6°C 
lower in formulation buffer containing sucrose, glycine, glutamic acid sodium 
chloride and polysorbate 80 (both at pH 3.0). Sucrose is known to stabilize the 
native protein structure, and an increase in Tm is observed for lysozyme in the 
presence of sucrose in a concentration dependant manner [Cueto et al., 2003]. 
The effect of amino acids on Tm of a given protein is more sophisticated, and 
contradictory statements can be found in the literature. Whereas increased 
thermal stability is reported for lysozyme, no effect on the Tm of bovine 
a-lactalbumine is seen for a number of amino acids [Sabulal et al., 1997]. An 
increase of Tm by increasing the NaCl concentration is reported for Interleukin-1 
receptor [Remmele, Jr. et al., 2000]. Thus, comparison and interpretation of Tm 
determined by DSC must take the pH and excipient conditions of the protein 
into consideration.  
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Figure 4-31: DSC curves of rhBMP-2 before precipitation (——–) and after dissolution 
of the precipitate (········) in 1 mM HCl (a) and in formulation buffer pH 4.5 
(b)  
The transition temperatures of rhBMP-2 before precipitation in aqueous HCl (pH 
3.0) and after precipitation, solubilization and dialysis into the same formulation 
are nearly identical (54.8°C vs. 54.6°C, Figure 4-31a). In addition, rhBMP-2 
precipitated, redissolved and dialyzed against formulation buffer results in the 
same Tm as the starting material in the same buffer (64.3°C vs. 63.9°C, see 
Figure 4-31b). These data strongly support the finding that the precipitation 
process itself does not induce any permanent changes and is fully reversible. 
Further increase of pH, phosphate and KCl concentration leads to rhBMP-2 
precipitation and a further increase in the transition temperature to 70°C (Figure 
4-30). Thus, the precipitated state of the protein goes hand in hand to improved 
thermal stability. In the precipitate, the associated protein molecules interact in 
a stabilizing manner with each other. To unfold their native structure, higher 
temperatures are necessary. A closer look at the calorimetric enthalpy further 
a 
b 
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supports the hypothesis that precipitation is reversible. Within the accuracy of 
the method, the calorimetric enthalpies of the 1 mM HCl samples are nearly 
identical (107.2 ± 7.0 kcal/mol vs. 103.4 ± 0.7 kcal/mol). For the rhBMP-2 sam-
ples analyzed in formulation buffer, the difference is more pronounced 
(107.0 ± 1.6 kcal/mol vs. 86.7 ± 1.3 kcal/mol). In general, calorimetric enthalpies 
below 100 kcal/mol indicate weak transitions, and results based on integration 
of such transitions were accompanied by higher errors. Therefore, 
interpretations should be done with care [Sanchez-Ruiz, 1995]. Nevertheless, 
the precipitated formulation exhibits the highest value in calorimetric enthalpy of 
all samples tested, arguing for its enhanced stability. 
4.2.1.2.5 DSC vs. ATR-FTIR 
The unfolding temperature of precipitated rhBMP-2 calculated from the intensity 
shift of the ATR-FTIR temperature ramp is slightly higher than the 
corresponding value determined by DSC (Table 4-6). In the resolubilized 
samples, the more pronounced difference is a consequence of the sample 
preparation. Excipients of the precipitation process (phosphate buffer salts and 
KCl) were not removed by dialysis in the resolubilized ATR-FTIR sample. 
Consequently, the higher pH and the presence of phosphate led to the higher 
Tm (spec.). Minor differences between Tm acquired with ATR-FTIR and DSC are 
expected, as there are fundamental differences between the techniques in the 
way of data analysis and the way of sample heating. In the spectroscopic 
approach, the sample is equilibrated at the measuring temperature and kept 
constant during the measurement with an effective heating rate of approx. 
0.7°C/min, whereas the sample is heated continuously in the calorimeter. 
Furthermore, Tm (spec.) is calculated as the temperature where the rate of 
intermolecular β-sheet formation is maximal (inflection point of sigmoid fit, 
Figure 4-29), whereas the temperature of maximal heat flux (at peak maximum 
in the thermogram, Figure 4-30) is considered to be Tm (calorimetry). 
Table 4-6: Comparison of unfolding temperatures of rhBMP-2 formulations 
determined with ATR-FTIR and DSC 
 Tm (spectroscopy) [°C] Tm (calorimetry) [°C] 
precipitated rhBMP-2 75.0 70.0 
resolubilized rhBMP-2 77.6 63.9 
 
4.2.1.3 Bioactivity of Redissolved Microparticles in Cell Culture 
Further evidence for the integrity of rhBMP-2 after redissolution of precipitated 
microparticles derives from cell culture experiments. The bone marrow stromal 
cell line W-20-17 shows increased alkaline phosphatase activity after incubation 
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with bioactive rhBMP-2 in a dose-responsive manner [Blum et al., 2000, Thies 
et al., 1992]. The inducible enzyme converts a non-colored substrate into the 
colored p-nitrophenol, which can be quantified by optical density reading at 
405 nm. The OD reading is transferred into potency by the use of a reference 
with an assigned value. The specific activity is calculated from the potency by 
dividing by the rhBMP-2 sample concentration used for enzyme induction. 
Figure 4-32 shows the results for rhBMP-2 which was immediately redissolved 
after precipitation. With a specific activity of 5.02*105 Uwho/mg for the sample 
and 5.08*105 Uwho/mg for the control, full bioactivity of the sample is 
demonstrated. 
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Figure 4-32: Specific activity of rhBMP-2 after precipitation and subsequent 
redissolution, compared to a native rhBMP-2 standard 
4.2.1.4 Summary 
Dissolution studies of precipitated microparticles demonstrate that the 
precipitation process did not induce the formation of higher amounts of 
aggregates. Furthermore, it could be shown by ATR-FTIR that the secondary 
structures of native liquid, precipitated and resolubilized rhBMP-2 are 
essentially identical. Analysis of thermal unfolding after precipitation and 
reolsubilization did not reveal any conformational alteration induced by the 
precipitation process. DSC measurements further confirmed these findings. No 
change in the transition temperature and process could be observed after 
precipitation and redissolution. Further evidence for the proteins integrity is 
provided by cell culture experiments, as no loss in bioactivity can be observed 
in resolubilized rhBMP-2 microparticles. Consequently, a precipitation process 
mimicking physiological conditions did not harm rhBMP-2 and is fully reversible. 
Thus, controlled precipitation is suitable to generate microparticles which can 
deliver native, active and intact rhBMP-2.  
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4.2.2 Storage Stability of rhBMP-2 in Microparticles 
4.2.2.1 Study Design 
Besides the exploitation of precipitation for the generation of relatively pure 
microparticles, protein precipitates might also serve as a tool to prepare highly 
concentrated formulations and as alternative to frozen or lyophilized storage, 
provided that the formulation is sufficiently stable. To address this issue and to 
determine storage conditions at which stability can be maintained, the influence 
of time and temperature on precipitated rhBMP-2 was evaluated. Furthermore, 
the benefit of a supplementary freeze drying step on protein stability of the 
precipitated formulation should be determined. The formulation commercially 
available as a lyophilisate serves as “gold standard”, and the pre-lyophilized 
formulation was included as reference for the aqueous dispersion. The 
precipitated formulations contain 1 mg precipitated rhBMP-2 dispersed in 100 µl 
aqueous, phosphate buffered solution (50 mM, pH 7.4), supplemented with KCl 
to physiologic ionic strength (154 mM). 1 ml reference formulation contains 
2.5 mg rhBMP-2, 0.5 % sucrose, 2.5 % glycine, 5.0 mM L-glutamic acid, 
5.0 mM sodium chloride and 0.01 % polysorbate 80 at a pH of 4.5. The samples 
were either freeze dried or preserved with 0.02 % sodium azide. A short 
overview of the study design, with images of the resulting formulations is given 
in Figure 4-33. The “liquid”, i.e. non-lyophilized aqueous precipitated dispersion 
delivers a thin, milky layer at the bottom of the vial, covered with residual liquid 
after centrifugation and removal of the supernatant. Subsequent lyophilization 
results in a dry and fragile flat disc. The “liquid” reference is a clear solution, and 
freeze drying of this formulation delivers a nice and fluffy lyophilization cake. 
Storage was carried out at -20, 4-8°C (in the following referred to 5°C), 25°C 
and 40°C for up to 10 months. The freeze dried samples were pre-closed with 
stoppers in the lyophilization chamber under vacuum. The liquid samples were 
prepared and closed at ambient conditions. After sealing, the sample vials were 
flanged and placed in storage.  
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Figure 4-33: Study design with images of resulting formulations 
4.2.2.2 Oxidation 
Among the variety of chemical instabilities [Goolcharran et al., 2000], rhBMP-2 
is known to be susceptible to oxidation and isomerization. Monitoring of these 
major degradation pathways was performed with peptide mapping, a method 
which has recently entered the European Pharmacopoeia.  
Oxidation of amino acid side chains is a common degradation seen in protein 
pharmaceuticals during storage. This chemical modification can induce changes 
in the structure that might alter bioactivity. Among the potential points of attack 
(Met, Cys, His, Trp and Tyr), Met is most susceptible to oxidation, as it can even 
be oxidized by atmospheric oxygen. Under these mild conditions, Met sulfoxide 
is the resulting degradation product. More potent oxidants are required to obtain 
Met sulfone [Manning et al., 1989]. RhBMP features two Met amino acids, 
Met371 and Met388, which are both subject to oxidation. By peptide map, 
oxidation of Met371 can be monitored, and the sensitivity of the formulations 
listed in Figure 4-33 at this site was evaluated. 
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precipitate reference precipitate reference 
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Figure 4-34: Oxidation of rhBMP-2 in different formulations after preparation (control), 
storage for 12 weeks and 40 weeks at -20°C 
The effect of refrigeration and storage at -20°C to minimize oxidation was tested 
only with a limited number of samples. The results are depicted in Figure 4-34. 
The liquid reference prepared by simple dilution of protein bulk material already 
shows approx. 2 % oxidation, marking the starting level for oxidation in the bulk 
product. The controls show similar levels for oxidation, calling for the 
maintenance of protein stability during the preparation procedure. After a slight 
increase in the values measured for 12 weeks storage, the determined amounts 
for oxidation decrease in the samples stored for 40 weeks. This observed 
decline is thought to mirror the accuracy of the assay, with variations of 1 to 2 % 
to be taken into account for interpretation. All samples stay well below 3 % of 
Met371 oxidation, suggesting that refrigeration at -20°C is suitable to prevent or 
at least minimize this degradation pathway. Within the accuracy of the 
measurement, no differences can be detected among the different freeze-dried 
and the liquid formulations. 
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Figure 4-35:  Oxidation over time in different rhBMP-2 formulations stored at 5°C 
At 5°C storage, only minor differences in the oxidation levels were measured 
over time. However, the data do not reveal a clear trend, suggesting that the 
observed variations are inherent to the method. Consequently, no significant 
oxidation can be detected under the applied storage condition (Figure 4-35). 
0
2
4
6
8
10
12
14
16
18
20
control 1w@25°C 2w@25°C 4w@25°C 12w@25°C 24w@25°C 40w@25°C
ox
id
at
io
n 
[%
]
aqueous dispersion
liquid reference
dried microparticles
dried reference
 
Figure 4-36: Oxidation over time in different rhBMP-2 formulations stored at 25°C 
At 25°C, degradation due to oxidation was monitored over 10 months (Figure 
4-36). Within the first two weeks, all formulations show acceptable low levels. 
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After storage for one month, the liquid reference clearly shows oxidation, and 
ongoing degradation led to a loss of almost 20 % within the observation period. 
In contrast, the “liquid”, precipitated formulation is stable, with oxidation levels 
comparable to the dried formulations, not exceeding 4 %. Within the dried 
formulations, no increase in oxidation can be observed over time. 
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Figure 4-37: Oxidation over time of different rhBMP-2 formulations stored at 40°C 
At 40°C, the ability of both liquid containing formulations to resist oxidation is 
considerably reduced, as depicted in Figure 4-37. Compared to the starting 
level and the levels for storage at lower temperatures, increased oxidation can 
be assumed in these formulations already after one week. A trend to higher 
resistance towards oxidation can be attributed to the aqueous dispersion as 
compared to the liquid reference. Superiority of the freeze dried formulations, 
both of the precipitated formulation and of the lyophilized reference compared to 
the aqueous dispersion becomes significant after 2 weeks. Whereas non-dried 
formulations hit the self-set specification of 5 % already at this time point, the 
freeze dried formulations stay below this level over the entire observation 
period. Among the dried systems, the approach based on precipitation shows 
slightly lower oxidation levels than the “gold standard”, the lyophilized product, 
affirming the trend already seen at 25°C.  
Thus, the formulations show increasing resistance to oxidation in the order 
liquid reference < liquid precipitated < dried reference < dried precipitated. 
Within the liquid formulations, higher oxidation rates were found at increased 
storage temperatures. A storage temperature of 25°C is sufficient to gain 
acceptable low levels for oxidation in the precipitated formulation. The liquid 
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reference requires lower temperatures (5°C) to stay below a tolerable oxidation 
level over the entire observation period. The increased oxidation resistance of 
the precipitate might be a consequence of limited access of oxygen to the 
relevant methionine residue buried within the precipitate. As expected, removal 
of water by lyophilization further improves stability. Due to the closure of the 
lyophilized samples under a vacuum of 0.04 mbar, the headspace of the vials 
theoretically contains approx. 4 % of the oxygen present in the liquid 
formulations, which were closed at ambient atmospheric pressure. Thus, the 
lower oxygen content in the lyophilized samples might also contribute to this 
result. The dried samples can be considered to be stable over the whole 
observation period at all tested temperatures. A direct comparison between the 
lyophilized and the dried precipitated formulations at each sample point delivers 
lower amounts of oxidized Met for the latter, giving rise to the assumption that 
this approach is slightly more potent in preventing oxidative degradation.  
4.2.2.3 Isomerization 
Due to the double bond like character of the amide C-N bond, the neighboring C 
atoms can adopt cis and trans conformations, with the latter being energetically 
favored. In X-Proline (X-Pro) peptide bonds, however, this energetic difference 
is leveled by steric destabilization of the trans conformation, thus increasing the 
incidence of cis conformers. Scheufler and co-workers demonstrated the 
presence of a cis-peptide bond for Pro present in the rhBMP-2 backbone 
[Scheufler et al., 1999], making isomerization at this site a thinkable scenario. 
For tissue plasminogen activator, peptide mapping in combination with mass 
spectrometric detection delivers four peaks, consistent with four possible 
isomers expected from two Pro residues in sequence [Ling et al., 1991]. But it 
was not possible to achieve distinct peaks with classic UV detection [Hancock, 
1995]. Consequently, in our studies utilizing HPLC in combination with UV 
detection for mapping digested rhBMP-2 samples Pro isomerization is not 
expected to be detectable.  
Another degradation process occurring in rhBMP-2 is the isomerization of 
aspartic acid (Asp). This pathway proceeds through a cyclic imide intermediate 
which might – depending on the environmental conditions - further degrade to 
isoAsp [Goolcharran et al., 2000]. X-isoAsp bonds are no longer cleaved by the 
enzyme Asp-N Endoproteinase deployed for peptide mapping. Therefore, the 
occurrence of uncleaved peptides which were formerly separated indicates Asp 
isomerization. This degradation is observed at two sites within rhBMP-2, but 
only alteration of Asp335 is used to monitor isomerization, as the second 
sensitive Asp is located in the propeptide sequence.  
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Figure 4-38: Isomerization of rhBMP-2 in different formulations after preparation 
(control), storage for 12 and 40 weeks at -20°C 
Figure 4-38 depicts isomerization of Asp335 immediately after preparation 
(control) and after storage at -20°C. Within the controls, comparable values for 
isomerization were determined, ranging between 2.2 and 2.6 %. This indicates 
that neither the precipitation process nor supplementary lyophilization causes 
significant isomerization. Data for 12 and 40 weeks storage also do not suggest 
accelerated degradation in any of the four formulations, qualifying subzero 
temperatures for long time storage. 
In Figure 4-39, the storage time at 5°C is plotted against isomerization with a 
logarithmic scale of the y-axis. Stability of the aqueous rhBMP-2 dispersion can 
be maintained, with values for isomerization not exceeding 5 % after 10 months 
storage. The liquid reference shows a clear tendency to isomerize, almost 
reaching 10 % degradation after 12 weeks and exceeding 20 % after 40 weeks. 
Both freeze dried formulations do not show significant changes over time, with 
isomerization values ranging between 2.7 and 3.5 % for the dried precipitate 
and slightly lower for the lyophilisate between 1.9 and 2.7 %. The subtle 
difference in isomerization levels between the two lyophilized samples is 
already seen after one week and continues over the whole storage time.  
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Figure 4-39: Isomerization over time of different rhBMP-2 formulations stored at 5°C 
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Figure 4-40: Isomerization of rhBMP-2 over time stored at 25°  
Figure 4-40 shows isomerization at 25°C, monitored over 10 months, again 
depicted on a logarithmic y-axis. The dramatic degradation of the liquid 
reference is dominating, leading to almost 80 % isoAsp formation after 6 
months. Compared to this, the increase in isomerization in the aqueous 
dispersion is quite moderate, being below 10 % for 6 months and ending up to 
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13 % after 10 months. In analogy to the findings at 5°C, the dried precipitate still 
shows slightly higher levels as compared to the lyophilized reference. 
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Figure 4-41: Isomerization over time in different rhBMP-2 formulations stored at 40°C 
The conversion of Asp to isoAsp after storage at 40°C is given in Figure 4-41. 
Again, the liquid formulation is most prone to isomerization. Already after one 
week, approx. one third of the protein fall victim to this type of degradation, and 
a loss of almost 80 % is observed within 3 months. In contrast, isomerization is 
greatly decelerated in the aqueous dispersion, leading to 80 to 90 % lower 
levels relative to the liquid reference with total numbers exceeding the bench-
mark of 10 after one month. However, the tendency to degrade is also evident, 
and the total amount of isomerized rhBMP-2 exceeds the benchmark of 10 % 
after one month storage. Again, a strong positive effect on protein stability can 
be seen for the dried formulations. Both the dry precipitate and the lyophilisate 
stay below 5 % over the entire observation period. Whereas in the lyophilisate a 
trend might be concluded by the continuous increase from 2.7 % isomerization 
after one week to 4.7 % after 3 months, the dried precipitate did not reveal such 
a trend, and the tendentially lower isomerization values randomize between 2.8 
to 3.8 %.  
Within the tested formulations, the liquid reference formulation shows the 
highest isomerization rates, with 80 % loss after 6 moths at 25°C or after 3 
months at 40°C. Disregarding the small difference between body and storage 
temperature of 40°C and assuming that liquid rhBMP-2 obeys the same 
degradation kinetics in the body than as in vitro, almost 50 % would be lost due 
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to isomerization after two weeks. Under the same conditions, only 6 % of the 
aqueous dispersion would be degraded. For storage, isomerization can be 
further decelerated in this formulation by reduction of the storage temperature to 
5°C, maintaining acceptable stability over 10 months. In both dried formulations, 
the discrepancy of isomerization levels is small. The difference is thought to be 
the consequence of unequal starting levels (Figure 4-38) which were preserved 
at 5 and 25°C over the course of the study. Thus, a definitive superiority of one 
formulation over the other cannot be derived from this data. At 40°C, however, 
the data suggest a slight advantage of the dried precipitate. Studies in aqueous 
solution with model hexapeptides containing Asp reveal a strong pH 
dependence of the degradation pathway, with basic pH values favoring isoAsp 
formation, whereas under acidic conditions, hydrolysis and cyclic imide 
formation are preferred. The reactivity of the carboxylic acid side chain is higher 
in the ionized form [Oliyai et al., 1993]. Consequently, higher isomerization is 
expected to occur in the liquid phase of the precipitated aqueous dispersion 
featuring a neutral pH. However, most of the protein molecules are existent as 
precipitate, thus minimizing the concentration of reactive molecules. In the 
precipitate, the molecules are separated from “mobile water”, leading to 
reduced protein mobility and therefore limiting the formation of the cyclic imide 
as intermediate step in isomerization.  
In general, higher storage temperatures accelerate the degradation, especially 
in the liquid-containing formulations. This can be explained by the equation of 
Arrhenius, which predicts a two to threefold speeding up of a reaction by a 
temperature increase of 10°C [Martin et al., 1987]. Compared to the rapid 
deterioration of the liquid reference formulation, the aqueous precipitated 
dispersion explicitly shows lower oxidation and isomerization levels due to the 
exclusion of “mobile” water, thus immobilizing rhBMP-2 in the precipitate. At 
25°C, the aqueous protein dispersion shows acceptable oxidation levels, but 
with 13 % isomerization, the degradation is quite high. At 5°C, stability over the 
entire observation period of 10 months is achieved without the need of drying or 
freezing, qualifying the aqueous precipitated dispersion as a long time storage 
candidate. Lyophilization is a well accepted and effective drying technique to 
gain protein pharmaceuticals with acceptable shelf lives [Wang, 2000]. Applying 
this approach on the liquid formulations effectively increases the chemical 
stability. At 5°C and 25°C storage, both the lyophilisate and the dried precipitate 
can be considered as equivalent. At 40°C, a slight superiority of the precipitated 
formulation for both isomerization and oxidation might be assumed.  
4.2.2.4 Aggregation 
Physical instabilities refer to changes in the higher order of protein structure, 
leading to denaturation, aggregation, adsorption or unwanted precipitation 
[Manning et al., 1989]. The native-like structure of rhBMP-2 precipitated under 
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controlled, physiological conditions and the reversibility of the precipitation 
process after immediate redissolution was already demonstrated (see 4.2.1). In 
the following, the maintenance of protein integrity during storage at reduced, 
ambient and accelerated temperatures should be investigated, focusing on the 
critical parameters aggregation, secondary structure and bioactivity. 
4.2.2.4.1 Soluble Aggregates Determined by SEC 
No difference in the aggregate content can be detected between the controls 
and the samples stored for 12 weeks at -20°C (Figure 4-42). The amount of 
aggregates found in the precipitated formulations is approximately half the 
amount found in the corresponding reference. As all formulations originate from 
the same protein stock solution, equal starting levels can be assumed. Conse-
quently, higher aggregate contents would be expected for the precipitated 
formulations, as these samples have experienced additional stress (caused by 
additional process steps: dialysis, precipitation, and resolubilization). Several 
explanations can be given: (i) reduction of the aggregate content intrinsically 
present in the bulk solution, e.g. by redissolution during dialysis into low acidic 
pH or potential separation by adsorption to sterile filter membranes, (ii) removal 
of soluble aggregates with the supernatant after precipitation and concentration 
of the precipitate by centrifugation, (iii) removal of aggregates by the 
centrifugation step generally performed in sample preparation for SEC. 
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Figure 4-42: Soluble aggregates of rhBMP-2 in different formulations during storage at 
-20°C 
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At a storage temperature of 5°C, all formulations stay well below 2 % aggregate 
content, and the increase seen over time is only marginal. In general, lower 
amounts of aggregates are found in the precipitated formulations, compared to 
the references, most probably a consequence of lower initial levels. The relative 
increase in aggregate content, compared to the starting level, is highest in the 
aqueous precipitate dispersion, followed by the dried precipitate, the liquid 
formulation and finally the lyophilisate. The absolute aggregate content of both 
precipitated formulations is initially the same, so the slower escalation in the 
dried formulation is indicative for its superiority. Whereas the lyophilisate shows 
a higher absolute aggregate content, the escalation is more rapid in the liquid 
precipitated samples, arguing for the superiority of the lyophilisate with respect 
to long time storage (Figure 4-43).  
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Figure 4-43: High molecular weight aggregate formation of rhBMP-2 in different 
formulations during storage at 5°C 
After storage at 25°C, a increase in aggregate content can be observed in all 
formulations over time (Figure 4-44). Aggregation in the lyophilisate is well 
below 3 %. The advantage of lower initial starting levels in the precipitated 
formulations gets lost, and after 4 weeks storage, the aggregate content 
exceeds the one of the corresponding reference. This trend is continued, and 
after 3 months, almost 5 % aggregates are found in the precipitated formu-
lations. Both the lyophilisate and the liquid reference stay well below 3 % 
aggregation, with slightly lower levels found in the latter.  
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Figure 4-44: High molecular weight aggregate formation of rhBMP-2 in different 
formulations during storage at 25°C 
The trend of higher aggregate content in the precipitated formulations, 
compared to the references, is even more pronounced in the 40°C storage 
samples (Figure 4-45), being obvious already after 1 week. After 3 months 
levels between 14-16 % are found in the aqueous precipitate dispersion and in 
the dried precipitate. Within the reference formulations, the aggregate content of 
the liquid reference formulation outran the value of the lyophilisate after 4 weeks 
storage. After 3 months, the absolute aggregate content is approx. 2.5 % higher 
than in the lyophilisate, which shows almost 5 % aggregates.  
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Figure 4-45: High molecular weight aggregate formation of rhBMP-2 in different 
formulations during storage at 40°C 
As a prerequisite for SEC analytics, the precipitated and the lyophilized samples 
needed to be redissolved. Consequently, aggregates might either already exist 
in the solid material or could be created at the instant of reconstitution from 
conformationally altered species. An explanation for the high aggregation 
tendency observed in the precipitated formulations at high temperatures might 
be the intimacy of precipitated molecules, making a reaction among each other 
more probable. Higher temperatures deliver the energy necessary to overcome 
the limited molecular mobility. For such a mechanism however, Pikal and co-
workers would expect an initial rapid increase in aggregates, followed by a 
decline as favorable configurations have already reacted. To explain a con-
tinuous increase – as it is seen in our experiments – they speculatively suppose 
that the formation of a conformationally altered intermediate might be the 
limiting factor for the rate of aggregation [Pikal et al., 1991]. The reduced 
aggregation tendency seen in the liquid reference can be explained by the 
presence of sucrose, which can act as thermodynamic stabilizer of the native 
conformation according to the concept of preferential exclusion [Kim et al., 
2003].  
4.2.2.4.2 Covalent and Non-covalent Aggregates by SDS-PAGE 
SEC provides information about the total aggregate content. To verify the 
obtained results and to get a deeper insight into the nature of the aggregation 
mechanism, SDS-PAGE was performed, allowing a differentiation between 
covalently and non-covalently linked aggregates (under reducing and non 
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reducing conditions, respectively). Due to the higher sensitivity, silver staining 
was used, accepting that this staining technique does not allow for accurate 
quantification [Jones, 1994]. Comparison of band intensities between different 
gels documenting different storage times is difficult, as the staining intensity 
within the individual gels varies considerably and attempts to correct this 
mathematically by referencing to a standard failed. Therefore, a relative 
evaluation of aggregation was performed, given in Table 4-7. 
Table 4-7: Aggregate content determined by SDS-PAGE: non-covalent aggregates 
were evaluated with ((-) < - < -- < --- < ----); samples containing covalent 
aggregates are with grey background (relative intensity parallels content)  
time 
[weeks] 
temperature 
[°C] 
aqueous 
dispersion
liquid 
reference 
dried 
precipitate
dried 
reference 
0 RT     
 -20     
1 5 (-) (-)   
 25 -- - - - 
 40 --- -- --- -- 
2 5 (-)  (-)  
 25 -- - -- -- 
 40 ---- --- ---- -- 
4 5 (-)  (-)  
 25 -- -- - -- 
 40 ---- --- ---- --- 
12 -20     
 5   (-)  
 25 -- -- -- -- 
 40 ---- --- ---- -- 
24 -20     
 5 - - (-) (-) 
 25 --- -- --- -- 
60 5 -- --  (-) 
 25 --- --- -- - 
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Non-reduced SDS-PAGE 
No aggregates are detected in the controls and in the samples stored for -20°C 
for 3 and 6 months, respectively. After storage at 5°C for one week, the band 
pattern of both reference formulations are identical to the internal rhBMP-2 
standard, with a very weak high molecular weight band indicating the presence 
of trace amounts of tetramer (consisting of four rhBMP-2 monomers, e.g. by 
combination of two naturally occurring dimers). In the aqueous dispersion and 
the dried precipitate, no high molecular weight species (HMWs) are present. At 
25°, weak bands are found in all formulations, becoming more distinct at 40°C. 
With slight variations, this pattern is also found after 2, 4 and 12 weeks storage. 
A new quality is introduced after 24 weeks storage, with aggregates already 
present at 5°C in all formulations. In general, the HMW bands in the precipitated 
samples are more intense than in the references, especially after storage at 
higher temperatures. 
Two distinct HMW species can be found in the aqueous dispersion, with 
molecular weights of 57-60 kDa and approx. 78-80 kDa. Aggregates in the 
liquid reference formulation and the dried formulations have molecular weights 
of 56-60 kDa and 69-73 kDa. With a molecular weight of 28-33 kDa for the 
native dimer and 14-17 kDa for the naturally occurring monomers, a molecular 
weight in the range of 56-60 kDa is consistent with a tetramer. After two week’s 
storage at 40°C, the aqueous precipitate dispersion exhibits an additional band 
with a molecular weight of approx. 44 kDa. After 4 weeks, the formation of 
hexamers is indicated by a band of 97 kDa, which fits well to the theoretical 
expectation of 84-100 kDa for this aggregate. 
The semi-quantitative analysis by visual comparison of band intensities delivers 
results which are in good agreement with SEC data. Both methods demonstrate 
a lower aggregate content at 5°C and higher levels after storage at elevated 
temperatures for the precipitated formulations as compared to the references.  
Reduced SDS-PAGE 
The gels performed under reducing conditions deliver additional information 
about the binding within the aggregates. In the dried precipitate stored at 40°C, 
covalent aggregates with a molecular weight of approx. 30 kDa are present 
after one week (Table 4-7). After two weeks storage at the same temperature, 
covalent aggregates are also found in the aqueous dispersion and the liquid 
reference. After 4 weeks, a faint band indicates the presence of covalently 
linked rhBMP-2 species in the lyophilized reference. The band intensities and 
thus the amounts of covalent aggregates differ considerably, with the bands of 
the precipitated formulations being more pronounced than in the references. 
The positive outcome at low storage temperatures, with absence of covalent 
aggregates at 5 and 25°C leads to a focus in the follow-up studies at these 
temperatures. After 6 and 10 months, small amounts of covalently linked 
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species are found in all formulations stored at 25°C. Therefore, only storage at 
5°C is useful to completely prevent covalent aggregate formation over 10 
months in all formulations. 
The covalently linked aggregates seen after reduction have molecular weights 
comparable to the native, non-reduced dimer. The band shape is consistent 
with the shape of the native, non-reduced rhBMP-2 dimer, featuring band 
doubling due to the naturally occurring isoforms of the differentiation factor. No 
high molecular weight aggregates, with masses comparable to those detected 
under non-reducing conditions can be found. This allows the conclusion that all 
HMW species detected under non-reducing conditions were non-covalent, and 
the covalent aggregate on reduced gels is most probably a rhBMP-2 dimer 
which has experienced some modifications so that it can no longer be 
separated into monomers under the applied reducing conditions.  
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Figure 4-46: Selected silver stained SDS-page gels, both non-reduced (a, b) and 
reduced (c, d): native rhBMP-2 reference (lane 1, 12); MARK12™ wide 
range standard (lane 2, 9); storage for 6 months of liquid formulation at 
25°C (lane 3) and 5°C (lane 4), aqueous precipitated dispersion stored at 
25°C (lane 5) and 5°C (lane 6), dried precipitate stored at 5°C (lane 7) and 
25°C (lane 8), lyophilisate, stored at 5°C (lane 10) and 25°C (lane 11) 
ba 
c d
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4.2.2.4.3 Secondary Structure Investigation by ATR FTIR 
It could be demonstrated by ATR-FTIR measurements that the precipitation 
process does not alter the secondary structure when redissolution is performed 
within a few hours (Figure 4-26). To study whether precipitate aging induces 
detectable conformational changes, samples of the precipitate in aqueous 
dispersion stored for 6 months at 5°C and 25°C were analyzed by ATR-FTIR 
and compared to both native liquid standard and the liquid reference treated at 
the same conditions. Figure 4-47 shows the area normalized second derivative 
spectra. No major difference can be detected between the samples stored for 6 
months and the control spectra of native rhBMP-2. Thus, as shown previously, 
aggregates detectable with SEC and SDS-PAGE in the stored samples at 5°C 
and 25°C cannot be picked up by FTIR which would pick up strong changes in 
the secondary structure.  
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Figure 4-47: Spectra of native liquid rhBMP-2 (——–), aqueous precipitate dispersion 
stored at 5°C (········) and 25°C (−−−−) and liquid rhBMP-2 reference 
formulation stored at 5°C (·−·−·−) and 25°C (··−··−) for 6 months. 
4.2.2.4.4 Bioactivity Testing of Aqueous Precipitate Dispersion  
In a small study, the intactness of precipitated rhBMP-2 was evaluated by 
bioactivity determination as a function of time and temperature. Non-preserved 
sterile aqueous dispersions were prepared. After storage at designated times 
and temperatures, the microparticles were concentrated by centrifugation, the 
supernatant was removed and the remaining pellet was redissolved in 
formulation buffer, frozen in liquid nitrogen and stored at -80°C until analysis. 
Dialyzed rhBMP-2 (1 mM HCl), which was used as starting material for the 
precipitated formulations, was included as standard. Furthermore, aqueous 
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dispersions of the storage stability study were also subjected to bioactivity 
determination. In Figure 4-48, each sample is faced with the internal control of 
fully bioactive protein.  
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Figure 4-48: Specific activity of precipitated rhBMP-2 after storage at different 
temperatures for 1, 10 and 28 and 90 days; grey bars represent samples, 
white bars the corresponding internal control 
Fully bioactive samples deliver specific activities in the magnitude of 
5*105 Uwho/mg, and a reduction by more than 2*105 units suggests serious 
damage of the protein. Accordingly, full bioactivity could be demonstrated for 
the aqueous dispersion. The absence of a systematic trend gives rise to the 
assumption that bioactivity will not be reduced during long time storage. The 
results also confirm full intactness of rhBMP-2 dialyzed into 1 mM HCl – the 
starting material for the precipitated formulation.  
4.2.3 Summary 
Evidence is provided that the controlled precipitation process does not disturb 
the integrity of rhBMP-2. Analysis with ATR-FTIR proves a native-like 
secondary structure of rhBMP-2 precipitated under controlled physiological 
conditions. Subsequent redissolution did not induce any changes demonstrating 
full reversibility. Further proof for the reversibility of rhBMP-2 precipitation is 
provided by DSC measurements, showing conformity of the melting tempera-
tures before precipitation and after precipitation and redissolution. Furthermore, 
the precipitate features an intense endotherm peak in the DSC thermogram, 
indicating that the protein is not unfolded and still possesses secondary struc-
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ture. Alterations in secondary structure of precipitated rhBMP-2, as seen during 
thermal unfolding in ATR-FTIR measurements, are non permanent and rever-
sible, as demonstrated in the unfolding spectra of the resolubilized sample. In 
addition, samples dissolved immediately after precipitation did not show a 
higher aggregate content and were fully bioactive in cell culture experiments.  
Precipitation shows a high potential to minimize the chemical instabilities iso-
merization and oxidation. With respect to the latter, the extensive degradation 
seen in the liquid reference can be greatly reduced, and rhBMP immobilized in 
the precipitated state maintains acceptable low oxidation levels at 25°C storage 
for 40 weeks. Quite impressive stabilization is also achieved regarding isomeri-
zation. Whereas the liquid reference formulation looses more than 68 % due to 
isoAsp formation, the aqueous precipitate dispersion shows only approx. 8.6 % 
after 24 weeks at 25°C, and keeps well below 5 % at 5°C storage. Thus, the 
liquid reference formulation would require storage at 5°C, the aqueous precipi-
tate dispersion can be stored at the higher temperature of 25°C and still 
maintains acceptable stability. Freeze drying of the aqueous precipitate 
dispersion delivers a stable formulation, enabling storage at 40°C for 40 weeks 
without significant increase in oxidation or isomerization. In addition, the 40°C 
data suggest a slight advantage of the precipitate, with otherwise comparable 
stability to the lyophilisate. The advantage, however, is alleviated by the fact 
that the precipitated formulation requires longer times for complete 
redissolution. Especially after long time storage at high temperatures, additional 
shaking was necessary to get a clear solution, with reconstitution times 
exceeding several minutes.  
The behavior of precipitation based formulations towards aggregation is 
ambivalent and strongly dependent on the temperature. At high storage 
temperatures, the reference formulations were superior, staying below 3 % 
aggregate content over 24 weeks at 25°C and 1 to 2 weeks at 40°C. Further-
more, irreversibly crosslinked rhBMP-2 dimers preferably occur in the 
precipitated formulations stored at higher temperatures, being slightly more 
pronounced in the dried precipitate. At 5°C, both the aqueous precipitate 
dispersion and the dried precipitate show lower absolute levels for aggregation 
than the corresponding liquid and freeze dried references. The maintenance of 
bioactivity in the aqueous dispersion was demonstrated over a period of three 
months at all temperatures tested, confirming the integrity of the protein. 
Consequently, precipitation can be used as a suitable tool for the preparation of 
highly concentrated rhBMP-2 formulations, and storage of the precipitated 
formulation at 5°C provides an alternative to lyophilization. 
ATR-FTIR is a useful tool to analyze and quantify the overall secondary 
structure of proteins. However, this technique does not allow the detection of 
aggregate formation in the dimension of 5 %. In addition, in a sample showing 
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17 % oxidation and 79 % isomerization (determined by peptide mapping), no 
change could be seen with ATR-FTIR. 
4.3 In-vitro Release from rhBMP-2 Microparticles 
4.3.1 Considerations and Setup 
Geiger describes the development of a suitable in-vitro release assay for a 
sustained release rhBMP-2 formulation based on ceramic/collagen composites 
[Geiger, 2001]. The major obstacles turned out to be the low solubility of 
rhBMP-2 in physiological fluids, the difficulty of quantifying small amounts of 
protein in large volumes of release medium and system inherent problems, 
such as interference of carrier decomposition products with the applied 
detection method. In addition, release could be greatly manipulated by the 
properties of the release medium, as the solubility of rhBMP-2 is very sensitive 
to the ionic strength and the presence of sulphate and chloride. Therefore, 
artificial buffer systems are considered to be no suitable release buffer 
candidates, and in-vitro release studies should be performed with serum. 
The development of an in-vitro release assay utilizing serum as release medium 
and at the same time avoiding radioactive labelleling or ELISA is challenging. 
To overcome the above described obstacles, release from rhBMP-2 
microspheres should be determined indirectly by quantifying the amount of 
protein still present in the microparticles at the designated time points. This 
approach has two advantages: (i) due to the sustained release of rhBMP-2 from 
disintegrating microparticles, a sufficient amount of protein is initially present, 
enabling rationale quantification; (ii) solid rhBMP-2 microparticles can be 
separated from serum by centrifugation, thus minimizing its interfering protein 
content. Figure 4-49 shows a microscopic image of rhBMP-2 microparticles 
suspended in human serum.  
 
 
Figure 4-49: rhBMP-2 microparticles suspended in human serum  
100 µm
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4.3.2 Analytic Development 
The feasibility of RP-HPLC and SDS-PAGE to separate rhBMP-2 from serum 
was tested, assuming that approx. 0.1 % serum will still be present in the 
sample after centrifugation, removal of the supernatant, and redissolution of the 
protein pellet. 
The applied RP-HPLC method does deliver two peaks, but baseline separation 
could not be achieved (Figure 4-50a). Variations in the performance parameters 
(decrease in flow rate, slower increase of organic solvent, longer run time) did 
improve the separation (Figure 4-50b). Nevertheless, the rhBMP-2 monomers 
were clearly eluted together with the major serum albumin peak. In addition, the 
modified run required higher sample volumes (100 µl instead of 50 µl), thus 
increasing the total amount of protein necessary for the analytic.  
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Figure 4-50: RP-HPLC chromatograms of artificial serum/rhBMP-2 mixtures: (a) 
standard run with 50 µI injection volume containing 0.1 mg/ml rhBMP-2 in 
0.1 % serum (b) modified run conditions with an injection volume of 100 µl 
containing 0.2 mg/ml rhBMP-2 in 0.1 % serum 
a
b
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The results suggest that the applied HPLC approach is principally suitable to 
separate rhBMP-2 from trace amounts of serum. For quantification, the small 
overlapping zone of the dimer peak with the serum could be overcome by a 
calibration based on peak high instead of peak area.  
 
 
Figure 4-51: SDS-PAGE gel electrophoretic separation of artificial rhBMP-2/serum 
mixtures: densitographs and corresponding gels (lane 1: marker, lane 2: 
serum / rhBMP-2 mixture (dotted), lane 3: rhBMP-2 (solid), lane 4: serum 
(dashed), lane 5: running buffer) for (a) non reduced (b) reduced samples.  
As an alternative quantification method, SDS-PAGE was tested. The 
densitographs of non-reduced samples show interference of both monomeric 
and dimeric rhBMP-2 signals with the background derived from serum (Figure 
4-51a). In the reduced samples, serum depicts only very weak signals in the 
region of the rhBMP-2 monomer bands (Figure 4-51b). Furthermore, reduction 
was thought to be an elegant way to increase the sensitivity by an increase of 
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the calibration peak area, which is then composed of the naturally occurring 
monomers and the monomers created by the conversion of the dimer into 
monomers. Consequently, the reduced variant is to be preferred. 
4.3.3 Calibration of Concentration Determination with SDS-PAGE 
Figure 4-52 shows the integrated optical density (IOD) of rhBMP-2 calibration 
samples, acquired with gel electrophoresis under reducing conditions and 
subsequent silver staining. No linearity is obtained within the concentration 
range of 0.01 - 0.4 µg protein load per lane. Furthermore, identical protein loads 
analyzed on different gels resulted in different IODs, indicating a high variation 
of staining intensity. The non-linearity of silver staining is also reported in 
literature, rendering this dye to be unsuitable for quantification [Jones, 1994].  
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Figure 4-52: Integrated optical density of silver stained calibration samples (reduced 
conditions) analyzed on three different gels: gel I (?) with 7 different 
concentrations, gel II (?) and III (?) with 5 calibration samples measured 
in duplicate. 
In contrast to silver staining, Coomassie blue staining is less sensitive, and 
protein loads of 0.1 to 1 µg were used for quantification. With this dye, an 
acceptable calibration can be achieved (Figure 4-53, R2 = 0.9881), and 
repeated analysis on different gels confirmed the linearity and the slope of the 
calibration.  
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Figure 4-53: Calibration curves for SDS-PAGE after Coomassie blue staining (reducing 
conditions): linear fit (―――) for a five point calibration (?) with samples 
run in duplicate; (?, ?, ?) three point calibrations performed on different 
gels  
In respect of sensitivity, Coomassie blue stained gels and the HPLC-analysis 
are quite similar. For the HPLC-approach, Geiger has determined the lower limit 
of detection in rhBMP-2 samples without an interfering serum peak to be 
approx. 0.1 µg per injection. Calibration of Coomassie blue stained gels was 
performed in the same concentration range. The gel electrophoretic separation 
is favored for two reasons. At first, separation from serum was more 
pronounced in the reduced gels than in the HLPC-approach. Secondly, samples 
containing high amounts of serum have been shown to negatively affect the 
performance of the employed separation column, possibly due to accumulation 
of serum proteins on the column [Geiger, 2001]. Consequently, there has been 
concern of a possible damage to the column by injecting serum containing 
samples, leading to reduced reproducibility.  
4.3.4 In-Vitro Release of rhBMP-2 from Microparticles in Serum 
D’Augusta investigated the release of radioactively labeled rhBMP-2 from 
collagen sponges in serum, performing full serum exchange at each sampling 
point [D'Augusta et al., 2000]. His work provides the framework of the 
experimental setup. RhBMP-2 release studies from microparticles were 
performed without and with partial serum exchange. 100 µl microparticle 
suspension containing 200 µg rhBMP-2 were added to 1 ml serum and 
equilibrated in eppendorff caps at 37°C in a shaking water bath. Serum 
exchange was performed by centrifugation to concentrate the rhBMP-2 
microparticles at the bottom of the vial, replacement of 500 µl serum with fresh 
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one, vortexing of the sample and putting it back into the shaking water bath. At 
designated time points, the sample was centrifuged, the supernatant completely 
removed, the residual protein microparticles present as pellet redissolved and 
stored at -20°C until analysis. The scheme of serum exchange and sampling for 
the setup with partial serum exchange is illustrated in Table 4-8.  
Table 4-8: Sample drawing and serum exchange scheme for in vitro release testing 
(? symbolizes sample #1, etc.) 
time [h] 1  4  24 72 168 336 
sampling ? ? ? ? ? ? 
exchange ????? ???? ??? ?? ?  
 
Figure 4-54 shows the release profiles for both setups. For comparison, the 
data obtained by D’Augusta for in-vitro release of rhBMP-2 from collagen 
sponge, with complete serum exchange at designated times, are also included. 
The release after 1 hour is the same for both setups, resulting in over 40 %. 
Without medium exchange, approx. 50 % is released after one day. The initial 
burst is followed by a period of minimal release, and after 14 days, 32 % of the 
initial protein content can be recovered as undissolved microparticles. Release 
is more rapid in the setup with partial serum exchange, increasing the release 
from 53 % to 85 % within the first day (with a total of 90 % of initial volume 
being replaced at this time point). After 14 days, no residual protein particles 
can be found, suggesting complete redissolution.  
D’Augusta obtained a release of 48 % within 1 day (the first measuring time 
point), increasing to 81 % after 14 days (Figure 4-54). The release profile of the 
microparticulate system shows a higher initial burst. At later time points, the 
obtained curve progression for the approach with serum exchange is similar to 
the release determined by D’Augusta. A difference can be seen in the total 
recovery. Whereas the microparticle system is completely dissolved after 14 
days, irreversible binding of rhBMP-2 on the sponge leads to a reduced 
recovery in this system. The approach without serum exchange shows 
enhanced retention, revealing the importance of medium exchange to reflect the 
in vivo situation.  
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Figure 4-54: Cumulative in-vitro release of rhBMP-2 in serum: rh BMP-2 microparticles 
without (?) and with approx. 45 % serum exchange (?) at each sampling 
time point; (?) rhBMP-2 loaded collagen sponge with total serum 
exchange at each sampling point 
A different behavior of the monomers building up the native rhBMP-2 dimer can 
be observed on the reduced gels, with the higher molecular weight monomer 
(representing the extended T form, see Figure 1-2) disappearing faster than the 
isomers of lower molecular weight (build up by the Q and <Q form). The faster 
fading of the high molecular weight monomer might be caused by the high 
hydrophilicity of the double extended homodimer (T/T isoform), thus 
redissolving faster than the more hydrophobic isoforms [Friess, 2000].  
4.3.5 Summary 
An in-vitro release assay was developed for rhBMP-2 microparticle formulation 
that allows the use of serum as release medium and utilizes SDS-PAGE for 
protein quantification. Whereas silver staining has proven to be unsuitable, 
good results are obtained with the Comassie blue dye. It could be demonstrated 
that the applied RP-HPLC is principally feasible to separate rhBMP-2 from 
serum. The obtained release profile for the microparticles is in good correlation 
to the data obtained for the release of rhBMP-2 from a collagen sponge. In 
contrast to the protein/carrier combination, 100 % release can be achieved from 
the microparticular system. A difference in the dissolution behavior of rhBMP-2 
isoforms is suggested, with dimers containing the extended monomer 
disappearing faster than the isoforms build up of the mature and isomerized 
monomers.  
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4.4 Efficacy Study in the Rabbit Distal Femur Intraosseous 
Model 
4.4.1 Study Design 
The efficacy of precipitated rhBMP-2 delivered as an injectable microparticle 
suspension to induce bone formation was evaluated. Rabbits serve as a 
qualified screening model as they feature a region at the distal femur between 
the condoyles of very low bone density (Figure 4-55). The rationale is to inject 
the rhBMP-2 formulation intraosseous into this region to augment bone density.  
 
Figure 4-55: Illustration of anatomic localization of injection site (adapted from 
www.freedictionary.com/chondyle) 
The study included 4 animals. A unilateral design was applied, i.e. one limb was 
treated with a total dose of 0.12 mg precipitated rhBMP-2 (300 µl microparticle 
suspension with a concentration of 0.4 mg/ml), whereas the contralateral limb 
serves as untreated control. Four weeks after injection, the rabbits were 
sacrificed. Analysis was performed by radiography and histology and data were 
compared with historic data of pure buffer and sustained releasing gel 
formulations. In-life radiographs were assessed at the time of surgery and two 
and four weeks post surgery. The trabecular bone volume was calculated as 
% bone area from VonKossa stained slides in the epiphyseal region (Figure 
4-56). Furthermore, the % difference from untreated controls was calculated. 
De-novo bone formation was qualitatively assessed by estimating the % surface 
of labeled trabecular bone area by visual inspection with a fluorescence 
microscope. Fluorochrome labelling was achieved by systemic administration of 
tetracycline 10 and 25 days post-op. The antibiotic forms chelate complexes 
with apatite, thus marking tissues which were mineralized at the time of dye 
administration.  
4.4.2 Study Outcome 
Radiography did not reveal dramatic differences in bone density both for the 
rhBMP-2 treated and the untreated control group (data not shown). The results 
of histomorphometric evaluation are listed in Table 4-9. Only a moderate 
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increase in trabecular bone volume, with a difference of approx. 9.5 % between 
rhBMP-2 microparticle-treated and untreated controls was found. 20-30 % of 
the bone surface area was labeled, suggesting a moderate bone formation 
activity. Compared to historic data of rhBMP-2 delivered in buffer, which shows 
an increase in trabecular bone area of approx. 8 % and de-novo bone formation 
in the range of 10-30 %, there seems to be no advantage of the precipitated 
formulation in this model. 
Table 4-9: Trabecular bone areas assessed by histomorphometry and fluorochrome 
labeling 
animal control 
(left) [%] 
treated 
(right) [%] 
difference 
[%] 
fluorochrome 
label [%] 
1 25.02 25.45 2 30 
2 37.70 40.41 7 30 
3 36.02 39.86 11 20 
4 28.00 32.96 18 20 
average 31.68 34.67 9.48 25.00 
SD 6.14 7.02 6.84 5.77 
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Figure 4-56:Sections of rabbit distal femurs after VonKossa silver staining and 
treshholding to black: (a-d) untreated controls (left femur of four animals) 
and right femurs (e-h) treated with rhBMP-2 microparticle suspension  
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In general, bone formation in small animals is much more rapid than in humans. 
Therefore, successful candidates in small animals will not necessarily lead to a 
positive result in large animals. In reverse, negative outcomes are likely to 
predict failure in large animals and humans [Seeherman et al., 2003]. With this 
respect, the identical outcome of the precipitated formulation compared to the 
liquid buffer formulation is disappointing. A possible explanation for the marginal 
effect might be an insufficient retention of rhBMP-2 the site of action. Either the 
microparticles themselves are quickly cleared off the injection site due to the 
high liquid exchange rate, or the release from the microparticles is to rapid, as 
indicated by the high in-vitro release obtained in the setup with serum exchange 
(Figure 4-54). A pharmacokinetic study with radioactively labeled protein would 
be helpful to identify the fundamental reason.  
A positive evaluation can be given with respect of immunogenicity. Although not 
explicitly tested, i.e. by monitoring inflammatory markers or specific anti-rhBMP-
2 antibody titers, the smooth course of the study, with any side reaction absent, 
suggests a good in-vivo tolerance of precipitated rhBMP-2 in the tested animal 
model. 
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5 Summary 
The present thesis focuses on the development and characterization of a novel 
formulation for the sustained delivery of recombinant human bone morpho-
genetic protein-2 (rhBMP-2). Based on the concept of precipitation, the known 
low solubility of the protein at physiological conditions was utilized to generate 
microparticles, delivering an aqueous protein suspension.  
RhBMP-2 has proven to induce bone formation. This ability can be applied to 
the field of bone tissue engineering, e.g. to support and accelerate bone 
regeneration at a skeletal site after fracture or in plastic surgery. For an optimal 
therapeutic effect, a prolonged presence of the morphogen at the site of action 
is required. As rhBMP-2 is rapidly cleared from the application site when 
administered as solution, it is usually combined with a carrier which retains the 
morphogen at the implantation site and provides its prolonged presence by 
sustained release. In the commercially available product the protein is soaked 
on a collagen sponge prior to implantation. The major disadvantage of this 
formulation is the necessity for invasive surgery to introduce the graft. With an 
injectable formulation, surgery could be avoided. In cases where operative 
treatment is necessary, an injectable formulation will be helpful in conjunction 
with a minimally invasive surgical technique. In addition, the treatment of 
fractures that do not require surgery will benefit from such a formulation (e.g. to 
enhance healing of simple, closed fractures). Finally, novel indications may 
arise for the multifunctional morphogen which extend beyond the treatment of 
skeletal diseases due to benefits from an injectable, sustained release 
formulation. Driven by the need, a number of injectable carriers for rhBMP-2 are 
currently under investigation, including calcium phosphate and sulphate 
cements, synthetic and natural polymers as gels or pastes and combinations 
thereof.  
The approach of this work was to create a ”carrier free”, injectable formulation 
which contains the protein as precipitated particles thus providing its own 
matrix. Release of active rhBMP-2 is thought to occur by sustained dissolution 
of the microparticles. In contrast to other micoparticulate approaches, a high 
protein load can be achieved with precipitation. In addition, the generated 
particles are already suspended in an aqueous vehicle, thus avoiding difficulties 
which may arise by dispersion of dry particles in a liquid.  
The first part of the thesis describes the development of a controlled 
precipitation process which allows the generation of uniformly sized 
microparticles. A simple experimental setup has proven to be suitable to obtain 
protein microparticles: in a batch mode, a turbulent rhBMP-2 bulk solution was 
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created with the help of vortexing and combined with a precipitation solution, 
and mixing was continued for a minute. Due to the composition of the solutions, 
an artificial physiological environment is created, forcing rhBMP-2 to precipitate. 
Laser light diffraction (LLD) with a modified sample cell which allows 
measurement of small sample volumes (< 5 ml) was deployed to characterize 
the precipitated microparticles. Particle formation was a time dependent 
process. Starting from an initially formed monomodal distribution, a second, 
larger population developed, leading to a bimodal distribution with maxima of 
approx. 7 µm and 35 µm after equilibration for one hour. Moderate 
centrifugation was reversible. After lyophilization and resuspension, the 
underlying bimodal distribution was broadened by an additional particle fraction 
exceeding 200 µm, observable both with LLD and in scanning electron 
microscopy (SEM) images. Lyophilization of highly concentrated precipitates 
greatly altered the particle distribution. Scaling-up of the batch precipitation 
process by increasing the final protein concentration and the batch volume was 
principally feasible, but is accompanied by the formation of associate species 
exceeding 200 µm. Improved scaling-up was obtained with a continuously 
operating precipitation procedure, utilizing a laminar mixing device. 
Independently from protein concentration and flow rate, similar particle size 
distributions were obtained than in the batch approach, but without the less 
desired large associates.  
Optimization of the formulation composition included the introduction of a 
suitable buffer system, elucidated by solubility studies of rhBMP-2 in various 
phosphate buffer systems. Clearance of excipients derived from the original 
protein stock formulation led to a basic standard formulation composed of 
rhBMP-2, phosphate buffer (50 mM, pH 7.4) and potassium chloride. Using this 
formulation, both the batch process and the continuous micromixer approach 
delivered similar bimodal distributions with prominent maxima at approx. 7 and 
34 µm. A slight advantage was seen for the laminar mixing approach due to the 
absence of any particles larger than 200 µm.  
In the course of the optimization process, phase contrast microscopy was 
evaluated as additional analysis tool. The images revealed particle sizes in the 
range of 1 to 10 µm, and loosely associated small particles form larger agglo-
merates which could easily be separated by slight shear forces. Consequently, 
the large aggregates detected with LLD had to be agglomerates of small 
particles. This finding was also confirmed by laser light blockade measure-
ments, showing that approx. 30 % of all particles have diameters of approx. 1.4 
µm, and no particle is larger than 50 µm (based on number distribution). Other 
visualization techniques, like (Environmental) SEM, delivered only limited 
information on the genuine particle distribution in suspension.  
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The addition of selected polyanionic biopolymers intended to achieve larger and 
more stable particles by coprecipitation as well as the addition of surfactants to 
prevent particle association did not lead to the desired effect. Homogeneous 
suspensions, with a particle size of 1-2 µm were achieved by increasing the 
viscosity of the aqueous vehicle. The primary particles were separated by the 
shear forces and reassembly is prevented by the limited mobility of the particles 
in the dispersant.  
The second part deals with the integrity of rhBMP-2 in the precipitated state and 
after redissolution. It was demonstrated that controlled precipitation did not 
harm rhBMP-2 and is fully reversible. With ATR-FTIR, native-like secondary 
structure was found in the precipitated microparticles. Secondary structure 
element determination resulted in 5 % α-helix and 25 % ß-sheet content. 
RhBMP-2 from redissolved microparticles also delivered native conformation, 
showing full reversibility of the precipitation process. The aggregate content 
after precipitation and resolubilization was not increased as compared to the 
starting material, proving that the precipitation process did not induce the 
formation of aggregation competent intermediates. Further evidence for the 
reversibility of precipitation derived from DSC measurements. Essentially the 
same melting temperatures were obtained before precipitation and after 
redissolution of precipitated microparticles. In addition, improved thermal 
stability for the precipitated material was indicated by a higher melting 
temperature and a higher value for the calorimetric enthalpy, as compared to 
the liquid formulation. Temperature dependent ATR-FTIR measurements of 
both the precipitated and the redissolved sample revealed a loss of α-helical 
and β-turn structures. This loss of native-like structure was not accompanied by 
an increase in unordered structures, but intermolecular antiparallel β-sheet 
structures were formed which are typical for thermally unfolded proteins. 
Analysis of redissolved rhBMP-2 in cell culture demonstrated full bioactivity.  
In addition, the potential of two precipitated formulation candidates – an aque-
ous dispersion and a freeze dried precipitate - to maintain protein stability over 
time was analyzed. Peptide mapping was implemented for the analysis of 
isomerization and oxidation during storage. Increased chemical stability was 
found for precipitated material, greatly reducing oxidation and isomerization 
compared to a liquid reference. Chemical degradation in the freeze dried 
precipitate was further reduced and comparable to the commercially available 
lyophilisate, meeting the stability criteria over the whole observation period. 
Aggregation as the major physical instability was monitored with SEC and gel 
electrophoresis. At high storage temperatures, both precipitated formulations 
showed higher sensitivity to aggregation than the references as indicated by 
increased aggregate contents and the appearance of covalently linked dimers. 
At 5°C storage, aggregation was reduced, leading to values comparable to the 
references. For up to 3 months, full bioactivity was demonstrated for the 
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aqueous precipitate formulation, and maintenance of conformational integrity 
was demonstrated over 6 months.  
ATR-FTIR has proven to be a good tool for determining the overall secondary 
structure of proteins. However, it failed to unclose an aggregate content in the 
order of 5 %, as determined by SEC, and high levels of isomerization and 
oxidation, as demonstrated by peptide mapping, suggesting that chemical 
degradation processes have no effect on the secondary structure of rhBMP-2.  
In the last part, the ability of the microparticle formulation to deliver rhBMP-2 in 
a sustained manner was tested. An in-vitro assay utilizing serum as release 
medium was developed. The difficulty to quantify rhBMP-2 in presence of serum 
was coped with a gel electrophoretic approach. In a setup with partial medium 
exchange, a high initial burst is followed by moderate release, suggesting a 
rapid dissolution, and complete disappearance of the particles within 14 days. 
The efficacy of the aqueous protein suspension to augment bone density was 
tested in rabbits. Compared to the untreated control, a moderate increase in 
trabecular bone volume of approx. 9.5 % was found. De-novo bone formation of 
20-30 % indicated a moderate bone formation activity. The results were com-
parable to the outcome for a liquid rhBMP-2 formulation. Thus, accelerated 
bone formation with the developed aqueous micorparticulate formulation could 
not be shown in this animal model. For optimization, the approach of increasing 
the viscosity of the dispersant appears promising. 
 
In conclusion, a simple precipitation step is useful to minimize chemical 
degradation of rhBMP-2 and can be utilized as alternative storage form at low 
temperatures. In addition, precipitation provides a useful tool for the preparation 
of highly concentrated formulations. Finally, the generation of microparticles by 
controlled precipitation is feasible. Consequently, controlled precipitation does 
have a great potential in formulation development, and transfer of this technique 
to other proteins is awaited. 
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06.12.2000 3rd part of the German examination in Pharmacy 
11/1999–02/2001 One year internship in a public pharmacy (Zeil-
Apotheke in Frankfurt/Main, Germany); subsequent 
employment as Pharmacist  
11/1995–10/1999 Studying Pharmacy at the Friedrich-Alexander-
University Erlangen-Nuremberg 
25.10.1999 2nd part of the German examination in Pharmacy  
29.08.1997 1st part of the German examination in Pharmacy  
03/1996–04/1996 Internship at the „Zeil-Apotheke“ in Frankfurt  
30.06.1995 Graduation with Abitur (German High School Diploma) 
at the Staatlichen Gymnasium Lauf an der Pegnitz  
